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On average, 21 people in the United States die every day while waiting for a 
transplantable organ. Moreover, at the end of 2014, nearly 130,000 additional individuals 
were still on the transplant waiting list. Xenotransplantation, the transplantation of cells 
and/or organs from a member of another species, is both a viable supplement for, and 
bridge to, allotransplantation. Pigs are the favored organ donor because they: 1) breed 
and grow rapidly, 2) can be genetically modified, and 3) present few ethical concerns. 
However, due in part to their phylogenetic distance, several barriers must be successfully 
overcome before clinical xenotransplantation can be fully realized. Antibody deposition 
is presently a barrier to successful cardiac, renal, and non-encapsulated islet 
xenotransplantation; although all xenografts are likely susceptible to antibody-mediated 
damage. The purpose of this dissertation is twofold: 1) to provide further molecular 
characterization of the elicited antibodies which mediate rejection of porcine xenografts, 
and 2) to identify clinically applicable small molecules capable of selectively inhibiting 
these antibodies. We have found that vascular pig xenografts, and isolated porcine 
pancreatic islets, both elicit antibody responses encoded by structurally related antibody 
gene progenitors. These structurally related antibody gene progenitors are both known to 
xv 
encode human antibodies capable of inhibiting clotting factor VIII (FVIII). Therefore, we 
subsequently identified FVIII as a novel xenoantigen, and provided a preliminary 
molecular analysis of the interaction between FVIII and the antibodies elicited after 
xenotransplantation. Additionally, our analyses strongly suggested that it was feasible for 
a single reagent to inhibit the majority of the antibodies elicited against transplanted 
xenografts. Consequently, we screened for, and identified, a single clinically relevant 
small molecule drug which, when tested in vitro, inhibited elicited antibody from 
multiple xenotransplant settings. However, it was only when utilized in combination with 
a previously identified experimental reagent that it was possible to reduce the post-
transplant antibody to levels below, or comparable to, those present before 
transplantation. These results challenge long-standing presumptions with regard to the 
nature of xenoantigens and their role in antibody-mediated xenograft rejection. 
Furthermore, identification of a clinically relevant selectively inhibitory small molecule 
should expedite transition into large animal work. 
 
 1 
CHAPTER ONE 
INTRODUCTION 
 
Introduction to Xenotransplantation 
In 1906, shortly after introducing a procedure for arterial anastomosis, Mathieu 
Jaboulay performed the first organ transplantation (1). However, it was not until after 
Frank MacFarlane Burnet and Peter Medawar’s discovery of acquired immunological 
tolerance in 1953 (for which they received the Nobel Prize 1960)(2), that successful 
transplantation was feasible. Thus, the first successful human organ transplantation took 
place in Boston on December 23, 1954, when a healthy monozygotic twin donated one of 
his kidneys to his brother (3). In the intervening decades, allotransplantation has been 
increasingly successful and is currently the favored treatment for end stage organ failure. 
In fact, it has been so successful that in 2013 in the United States, 28,473 people received 
at least one donor organ (4). Soberingly, over four times this number of individuals were 
still waiting for a transplant in February of 2015. On average, 21 people on the waitlist 
die every day. Moreover, the number of patients included on the waitlist is misleading 
given that it is limited by the treatment modalities available to sustain patients while 
waiting for a suitable donor organ. For instance, kidney transplant patients typically 
account for about 80% of the waitlist because they can be sustained for years by 
hemodialysis. Moreover, individuals over 65 years of age make up approximately half of 
the waitlist but receive only one fifth of the available transplants. This growing 
discrepancy between supply and demand has spurred investigation into alternative 
treatments for end stage organ failure. 
 2 
Xenotransplantation, the transplantation of cells and/or organs from a member of 
another species, is both a viable supplement for, and bridge to allotransplantation. In New 
Zealand, encapsulated pancreatic porcine islets have recently demonstrated safety and 
efficacy in treatment for type 1 diabetes in early phase clinical trials (5). Furthermore, 
non-life supporting models of pig-to-primate cardiac xenotransplantation have 
demonstrated survival up to almost 600 days (6). Pigs have been considered the favored 
xenotransplant organ donors for over two decades. Unlike primates (which are 
phylogenetically closer to humans), they breed and grow rapidly making it possible to 
meet the growing demand for donor organs (7). Furthermore, pigs can be genetically 
modified and present fewer ethical concerns. However, due in part to their phylogenetic 
distance, several barriers must be successfully overcome before clinical 
xenotransplantation can be fully realized. 
 
Knocking Out the Galactosyltransferase Gene 
When he performed his first transplantation experiment in 1906, Mathieu 
Jaboulay found that humans reject porcine organs almost immediately (1). It wasn’t until 
1988, that Uri Galili et al. demonstrated old world monkeys and humans differ from other 
mammals in that they do not express the Galα1,3-Galβ1,4GlcNAc-R (Gal) terminal 
carbohydrate (8). This led several group in the early 1990’s to provide preliminary 
evidence (9, 10) that anti-Gal antibodies, which make up as much as 1% of circulating 
IgG in humans (11, 12), were responsible for hyperacute xenograft rejection of porcine 
xenotransplants (10, 13). Over the next decade, several methods were employed in 
attempt to prevent hyperacute rejection.  
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One of the most successful methods utilized pig donors expressing transgenes for 
human complement regulatory proteins (14-16). These transgenes were considered 
necessary to compensate for the molecular incompatibility between human serum 
complement proteins and pig cell membrane-bound complement regulatory proteins. 
However, enhanced regulation of complement activation, initiated by anti-Gal antibody 
bound to the graft vasculature, only sustained xenograft survival long enough to endure a 
newly elicited anti-Gal antibody response (17). 
The process of cloning using somatic cell nuclear transfer, first utilized to 
generate Dolly the sheep (18), enabled the production of pigs which did not express Gal 
(19-21). These pigs, which did not carry a functional allele of the GGTA1 gene 
responsible for the synthesis of the Gal epitope (galactosyltransferase gene knockout; 
GTKO), were generated in 2003 by Revivicor (a spin-out from the UK company PPL 
Therapeutics which produced Dolly). To the excitement of scientists in the field in 2005, 
when baboons were transplanted with GTKO pig hearts (22, 23) or kidneys (13, 24) they 
did not succumb to hyperacute rejection nor did they develop anti-Gal antibodies after 
cessation of pharmacologic immunosuppression. However, these grafts still showed signs 
of antibody mediated rejection, albeit with kinetics and pathology consistent with delayed 
humoral xenograft rejection. 
 
Anti-Non-Gal Antibodies 
Even before the era of GTKO pigs was ushered in, anti-pig antibodies directed at 
antigens other than Gal (non-Gal) were under investigation. In 1998, experimental 
evidence from Mauro Sandrin’s group using GTKO mouse recipients demonstrated that 
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anti-non-Gal antibodies could also mediate damage to xenografts (25)[Confirmed in (13, 
26, 27)]. Additionally, work performed by Leo Buhler and David Cooper in 2003 
provided early evidence that antibodies against non-Gal antigens elicited in baboons after 
cardiac xenotransplantation were not donor specific (28) [Confirmed in (29)]. 
In 2006, pre-existing anti-non-Gal antibodies were characterized as distinct from 
antibodies directed against human allografts (30, 31). Thus, sensitivity to 
allotransplantation would not preclude xenotransplantation, nor would sensitivity to 
xenotransplantation preclude allotransplantation. Therefore, xenotransplantation could be 
utilized as a short-term bridge to allotransplantation or, eventually as a long-term 
treatment option for patients with high alloantibody titers. 
Fortunately, it is well documented that the majority of individuals have anti-non-
Gal antibodies which pre-exist at levels too low to initiate xenograft damage (32, 33). 
Consequently, newly elicited anti-non-Gal antibodies present the greater barrier to 
successful clinical xenotransplantation. Work by Muhammad Mohiuddin, using non-life 
supporting models of cardiac xenotransplantation, best illustrates the impact of elicited 
anti-non-Gal antibodies on xenograft survival. In 2012, the singular addition of a B-cell 
depleting anti-CD20 antibody to the immunosuppressive regimen extended median 
xenograft survival from 8 days to 71 days, now with a maximum survival time of 236 
days (34). Furthermore, modifying the pharmacologic method of inhibiting B-cell co-
stimulation by T cells extended the xenograft survival of one animal to approximately 
600 days at the time of publication in 2014 (6). However, in the context of 
transplantation, B cell depletion is known to result in a greater risk of infection and 
infection-related death (35-37).  
 5 
Non-α-1,3-Gal Antigens 
Identification and characterization of the antigens present in GTKO pig tissues 
which initiate antibody-mediated rejection should expedite the development of strategies 
to enhance xenograft survival. For instance, the gene which encodes the antigen could be 
deleted. Alternatively, a soluble version of the antigen could be utilized to selectively 
inhibit/deplete xenograft-rejecting antibodies and B cells. Moreover, analysis of the 
functional impact of antibodies which mediate rejection may reveal complement-
independent antibody-mediated pathology. 
Even before the first knockout pigs were generated, there were several candidate 
non-Gal antigens. In addition to anti-Gal antibodies, humans are also known to have pre-
existing antibodies against N-glyconeuraminic acid (Neu5Gc), α–lactosamine, and the 
Forssman antigen, among others (38, 39). It was also conceivable that deletion of the 
GGTA1 gene may have significantly altered glycosylation patterns or exposed internal 
carbohydrate moieties creating novel immunogens (40). Additionally, early evidence 
suggested that anti-non-Gal antibodies might bind protein epitopes (28, 41). Over the last 
decade, several new candidates have been identified while others have been deemed 
unlikely. However, the identification of the relevant immunogen(s) present on GTKO 
organs and cells is still an ongoing area of investigation. 
After the knockout of the GGTA1 gene, Mauro Sandrin’s group was concerned 
that GTKO pigs might still express residual Gal epitope. GTKO mice had only recently 
been determined to express the Gal carbohydrate in the form of a glycolipid, named 
isoglobotrihexosylceramide, due to the presence of a functional GGTA2 gene (40, 42, 
43). However, thorough analyses of glycolipids in GTKO pig intestine, pancreas, heart, 
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and kidney have observed an absence of isoglobotrihexosylceramide present in porcine 
tissues (44-46).  
In 2010, David Cooper’s lab investigated the most plausible non-Gal 
carbohydrate antigens using naïve human, baboon, wt pig, and GTKO pig sera (47). This 
study found that GTKO pigs did not express the Forssman carbohydrate antigen while 
anti-lactosamine antibodies were not elicited against GTKO xenotransplants. Thus, 
neither α–lactosamine nor the Forssman carbohydrate were considered likely non-Gal 
antigens. However, perhaps the most important finding of this study was that human 
serum, but not baboon or pig serum, contained antibodies which bound Neu5Gc 
indicating that Neu5Gc is only pertinent in pig-to-human xenotransplantation.  
Initial suspicions that disrupting the GGTA1 gene would alter glycosylation 
patterns were well founded. Compared to wt pigs, GTKO pigs were determined to have a 
higher expression level of sialic acid residues, including Neu5Gc (46, 48). By 2013, 
Joseph Tector’s group had generated pigs in which both the GGTA1 and CMAH genes 
were knocked out, and therefore expressed neither Gal nor Neu5Gc (49). As expected, a 
smaller proportion of naïve human IgM bound to double knockout pig cells than to 
GTKO pig cells (50). Furthermore, erythrocytes from double knockout pigs were less 
susceptible to damage mediated by antibodies in human sera when compared to red cells 
from GTKO pigs (51). However, erythrocytes from double knockout pigs were more 
susceptible when using baboon sera because unlike humans, baboons express Neu5Gc. 
Thus, illustrating that while GGTA1/CMAH double knockout pigs will be important for 
clinical xenotransplantation, they will likely complicate experiments using non-human 
primates. 
 7 
Interestingly, a portion of pre-existing anti-Neu5Gc antibodies also bind 
fibronectin from GTKO pigs (52). However, not all pre-existing antibodies against 
fibronectin from GTKO pigs bind Neu5Gc. Fibronectin was first identified as a non-Gal 
antigen in 2008 by Guerard Bryne and Christopher McGregor (53). They utilized 
proteomic techniques, including western blotting, 2-D gel electrophoresis, and mass 
spectroscopy, to identify a number of targets which bound IgG antibody eluted from 
rejected GTKO pig hearts. Many of the proteins bound by the eluted IgG were deemed 
unlikely to initiate xenograft rejection given their intracellular location. However, given 
that fibronectin is an extracellular matrix protein expressed by endothelial cells, 
antibodies against fibronectin could plausibly initiate xenograft rejection. Importantly, in 
2013, further study by Joseph Tector’s group revealed that pre-existing human antibodies 
against pig fibronectin can elicit cytotoxicity of GTKO pig endothelial cells (52). 
In recent years, Guerard Byrne and Christopher McGregor have provided 
evidence that the porcine β1,4 N-acetylgalactosaminyl transferase (B4GALNT2) is 
responsible for the synthesis of a novel carbohydrate non-Gal antigen (54, 55). This gene 
was first identified in 2011 using an expression library screening strategy in which 
mRNA from GTKO pig aortic endothelial cells was expressed in human embryonic 
kidney (HEK) cells (54). Expression of the porcine B4GALNT2 was identified to 
enhance binding of IgG from sensitized cardiac xenograft recipients. Further research in 
2014 demonstrated that compared to normal HEK cells, HEK cells expressing porcine 
B4GALNT2 showed increased sensitivity to antibody-dependent complement-mediated 
cytotoxicity assays which made use of serum from GTKO xenograft sensitized baboons 
 8 
(55). Notably, absorbing antibodies on GTKO pig aortic endothelial cells beforehand 
dramatically reduced this effect. 
 
Antibody-Mediated Xenograft Rejection 
When pig organs are transplanted into non-human primates, rejection is a 
complicated process that results from interplay among a multitude of intricately related 
factors, including: the method and/or site of transplantation [reviewed in (56)], the organ 
being transplanted [reviewed in (57-60)], the immunosuppressive regimen utilized 
[reviewed in (61)], the donor genetics [reviewed in (62)], the donor source (63), the 
remaining molecular incompatibilities, the innate immune system [reviewed in (64)], 
activation of the adaptive immune system (see below), and coagulative dysregulation 
[reviewed in (65)]. However, experimental manipulation and histological evaluation of 
both wt and GTKO vascularized xenografts has indicated that vascular antibody 
deposition is a prime initiator of xenograft rejection in certain settings (13, 22, 34, 58, 60, 
66-68). Although all xenografts are likely susceptible to antibody-mediated damage, there 
are only a few organs whose survival is currently limited by humoral mechanisms. 
Generally, xenografts must survive long enough for adaptive immunity to be relevant. 
Therefore, antibody-mediated rejection of vascular xenografts is currently most pertinent 
in cardiac and renal xenotransplantation. Additionally, it has recently been accepted that 
antibody-mediated damage is detrimental to engraftment of non-encapsulated pancreatic 
islets (26, 59, 69). Therefore, when developing novel interventions designed to enhance 
xenograft survival and function, an understanding of the mechanisms of antibody-
mediated xenograft rejection are of the utmost importance. 
 9 
The kinetics of antibody-mediated xenograft rejection are dependent on the 
abundance of graft-reactive antibody present in the recipient. In the absence of 
immunosuppression, xenotransplantation of wt pig organs results in hyperacute rejection 
which takes place within minutes to hours (70, 71). This is because pre-existing anti-Gal 
antibody is exceedingly abundant. In similar circumstances, xenotransplantation of 
GTKO pig organs only succumb to accumulation of newly elicited anti-non-Gal 
antibodies within 3-14 days, depending on the sensitivity of the graft (27, 72). 
Unfortunately, even with a robust immunosuppressive regimen, rejection associated with 
de novo production of anti-pig antibodies (termed delayed humoral xenograft rejection), 
can take place weeks, or even months after transplantation (68). Thus, suppressing the 
majority of the adaptive immune system has become the prevailing approach to 
xenotransplantation. However, the relationship between the rejection kinetics and the 
abundance of graft-reactive antibody can also be altered by modifying antibody-antigen 
interactions (73-75), as well as downstream components of rejection (14, 16, 72, 76, 77). 
Histologic examination after antibody-mediated vascular xenograft rejection 
reveals that in addition to vascular antibody deposition there is complement deposition 
and platelet-rich fibrin thrombosis (22, 78, 79). Of note, serial biopsies of GTKO cardiac 
xenografts reveal that vascular antibody and complement deposition precede histologic 
and systemic evidence of damage. Furthermore, the extent of antibody and complement 
deposition parallels the degree to which indications of damage are apparent.  
Vascular antibody and complement deposition cause endothelial cell activation by 
catalyzing the formation of the membrane attack complex (27, 66, 67, 79) (Figure 1). 
Regrettably, membrane bound porcine complement regulatory proteins do not adequately 
 10 
regulate soluble primate complement cascade components [reviewed in (80)]. However, 
transgenic expression of human complement regulatory proteins (CD59 Figure 1A, 
CD46, CD55, Figure 1B-C) can raise the threshold of antibody required to elicit 
complement-mediated vascular damage (14-16). For this reason, it is currently accepted 
that vascular GTKO xenografts will need to express at least one of these human 
complement regulatory transgenes. 
 11 
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Once activated, endothelial cells express tissue factor (TF) and von Willebrand 
factor initiating fibrin deposition and platelet activation (Figure 2A-B). Even if formation 
of the membrane attack complex is averted, byproducts of antibody-mediated 
complement activation (C3a and C5a) can also activate and recruit host neutrophils and 
monocytes (81). In turn, induction of recipient TF on neutrophils and monocytes can 
contribute to development of consumptive coagulopathy (Figure 2C) characterized in part 
by thrombocytopenia (low platelet count), declining fibrinogen (fibrin precursor) levels, 
and prolonged clotting time (82, 83). It has long been postulated that these effects could 
be tempered by transgenic expression of human thromboregulatory proteins such as 
tissue factor pathway inhibitor or thrombomodulin. GTKO pigs expressing such 
transgenes have only recently been utilized as experimental organ donors. However, they 
are typically present in the context of complement regulatory transgenes. At this time, in 
vivo experimentation has yet to tease out the contribution to survival with the addition of 
each transgene. However, recent findings suggest that transgenic overexpression of 
human tissue factor pathway inhibitor (84), or thrombomodulin (6), can attenuate 
coagulative dysregulation and may set the threshold for rejection even higher. 
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Islet Xenotransplantation 
Similar mechanisms contribute to destruction of non-vascular xenografts such as 
non-encapsulated islets. Anti-pig antibodies, along with TF expressed on isolated islets, 
induce what is called instant blood-mediated inflammatory reaction (IBMIR)(26, 59, 69, 
85). IBMIR dramatically reduces the proportion of isolated islets which remain viable 
after transplantation. Therefore, a greater number of donors is required to pool enough 
islets to ensure enhanced control of blood glucose. Graft TF initiates fibrin deposition and 
platelet activation. Additionally, antibody-mediated complement activation triggers 
complement-mediated graft damage through the terminal complement membrane attack 
complex and activation and recruitment of neutrophils and monocytes via complement 
cleavage products. Just as with vascular grafts, activated recipient neutrophils expressing 
TF can exacerbate local coagulative dysfunction by contributing to fibrin deposition and 
platelet activation. Fortunately, recent evidence suggests that expression of complement 
regulatory (85), and thromboregulatory transgenes (86), diminish IBMIR and enhance 
survival of islet xenografts. After cessation of IBMIR, destruction of xenotransplanted 
islets is considered to be a primarily T cell-dependent processes. Of note, several groups 
have reported xenograft survival over 1 year in non-human primates (86-88)(Table 1) and 
transplantation of encapsulated pig pancreatic islets is currently in clinical trials (5).  
 
Renal Xenotransplantation 
When co-transplanted with pig thymic tissue, GTKO kidney xenografts have a 
reported record survival time of 83 days (24, 78, 89)(Table 2). However, the record 
median survival is only 49 days, even though recipients develop donor-specific 
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hyporesponsiveness. Histologic examination in these cases reveals antibody-mediated 
glomerulopathy, with thrombosis of the glomerular microvasculature (thrombotic 
microangiopathic glomerulopathy) and effacement (lengthening/thinning) of podocyte 
foot processes (90). Pre-existing anti-pig antibodies have recently been reported to 
disrupt podocyte morphology and function leading to rejection of GTKO kidney 
xenotransplants (91). Thus, in some settings, antibody-mediated damage more directly 
effects xenograft function. Approaches which stabilize podocyte integrity or 
inhibit/neutralize anti-pig podocyte antibodies will likely extend renal xenograft survival. 
 
Cardiac Xenotransplantation 
Recent advancements in the field of cardiac xenotransplantation have provided 
new hope that clinical xenotransplantation is on the horizon (6, 34, 92). The record 
median survival of non-life supporting cardiac xenografts was previously 96 days with a 
maximum of 137 days (73)(Table 3.1). This record was set in 2005 utilizing hCD46 
transgenic organs. However, refinements of the immunosuppressive regimen, donor 
genetics, and quality of post-transplant monitoring have lengthened median survival to 
over 200 days, with at least one graft reported be survive for approximately 600 days at 
the time of publication in September of 2014 (6)(Table 3.11). At this time, life supporting 
models of xenotransplantation have yet to catch up and survival is limited to a maximum 
of 57 days (93)(Table 3.A). However, this record will likely be surpassed following suit 
with non-life supporting models. In spite of this success, antibody-mediated damage 
plays a large role in cardiac xenograft rejection and possibly chronic damage of cardiac 
xenografts. Antibody was found on the explanted xenografts in each of the 
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aforementioned settings. Additionally, biopsies from surviving hearts still demonstrated 
vascular antibody deposition, in addition to fibrosis as early as postoperative day 182. 
This suggests that chronic vascular deposition of antibody, even at low levels, may 
steadily contribute to loss of function (6). The relationship between antibody deposition 
and graft damage in these animals is still under investigation. 
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   Table 1 GTKO and record islet xenotransplantation experiments since 2005 
 
 
  
First Author (year) Donor genetics Recipient (n) Immunosuppression (anti-coagulation) Survival in days  (median)
1 Rood (2007) GTKO adult
Cynomolgus 
monkey (n=2)
ATG, tacrolimus, rapamycin +/- anti-CD20mAb 
(n=1), (heparin)
<5
Cynomolgus 
monkey (n=3)
ATG, anti-CD154mAb, MMF, CVF (heparin, +/-
prostacyclin, aspirin)
5 to 7
Cynomolgus 
monkey (n=2)
ATG, anti-CD154mAb, MMF (dextran sulfate, 
prostacyclin, aspirin)
> 58 (partial function)
2 Rogers (2007) WT
rhesus monkey 
(n=3) 
No IS [multiple Txs; mesenteric] 78 to 409
3
van der Windt 
(2009)
WT and GTKO
cynomolgus 
monkey (n=2)
ATG, anti-CD154mAb, MMF, CS (dextran sulfate, 
prostacyclin)
7, 20, 31, 46
CD46
cynomolgus 
monkey (n=5)
ATG, anti-CD154mAb, MMF, CS (dextran sulfate, 
prostacyclin)
planned 3 months [87, 91, 92, 
~90 (partial)]; selected for long 
term follow up [396]
4 Thompson (2011) GTKO
rhesus monkey 
(n=5) 
Anti-CD154mAb, anti-LFA1mAb, MMF, CTLA4-Ig 
(heparin)
n/a, 50, 91, 99, 249                   [4/5 
insulin independence]
Hemizygous GTKO 
(effective WT)
rhesus monkey 
(n=5) 
Anti-CD154mAb, anti-LFA1mAb, MMF, CTLA4-Ig 
(heparin)
4x n/a; 137                                [1/5 
insulin independence]
5 Bottino (2014) GTKO/CD46/CD39
cynomolgus 
monkey (n=1)
CS, ATG, MMF, anti-CD154mAb (dextran sulfate, 
prostacyclin, aspirin)
5
GTKO/CD46/TFPI/CTL4-Ig
cynomolgus 
monkey (n=2)
CS, ATG, MMF, anti-CD154mAb (dextran sulfate, 
prostacyclin, aspirin)
0, 365
GTKO/CD46/TFPI/CTL4-
Ig/CD39
cynomolgus 
monkey (n=2)
CS, ATG, MMF, anti-CD154mAb (dextran sulfate, 
prostacyclin, aspirin)
3, 160
ATG - anti-thyroglobulin, CS - corticosteroids, CVF - cobra venom factor, IS - immunosuppression, MMF - mycophenolate mofetil
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First Author (year) Donor genetics Recipient (n) Immunosuppression
Survival Range in days  
(median)
1
Yamada (2005) GTKO Baboon (n=6)
(thymokidney) +/- WBI, thymectomy, splenectomy, anti-
CD2mAb, anti-CD154mAb, MMF, CS, +/- CVF
4 to 68 (32)
2
Chen (2005) GTKO Baboon (n=3) ATG, tacrolimus, CS 8, 10, 11
Baboon (n=3) ATG, tacrolimus, CS, MMF, CVF 9, 13, 16
3
Griesemer (2009) GTKO Baboon (n=7)
thymectomy, splenectomy, TBI (n=1), ATG +/- anti-CD2mAb, anti-
CD154mAb, tacrolimus, MMF, anti-CD20mAb
18 to 83 (49)
4
Lin (2010) GTKO/CD46 Baboon (n=1) no IS 2
5
Griesemer (2010) GTKO Baboon (n=2)
TBI, TI, splenectomy, ATG, anti-CD2mAb, tacrolimus, GTKO BMTx, 
+/- CVF (n=1)
8, 11
6
Nishimura (2011) GTKO Baboon (n=2)
(thymokidney) thymectomy, splenectomy, anti-CD3IT, +/- anti-
CD2mAb, ATG, anti-CD20mAb, tacrolimus, anti-CD154mAb, MMF
15, 15
7
Le Bas-Bernardet 
(2011)
GTKO/CD55/CD59/CD39 Baboon (n=2) No IS 3, 4
GTKO/CD55/CD59/CD39/HT Baboon (n=4) splenectomy (n=2), CyP, tacrolimus, MMF, CS, C1-INH 4, 12, 13, 15
8
Shimizu (2012) GTKO Baboon (n=2) ATG, anti-CD2mAb, anti-CD154, MMF, CS 20, 33
Baboon (n=1)
thymectomy, splenectomy, TBI, ATG, anti-CD2mAb, anti-CD154, 
MMF, CS
34
Baboon (n=4)
(thymokidney) thymectomy, splenectomy, ATG, anti-CD2mAb, 
antiCD154mAb, MMF, CS, +/- TBI (n=1)
56, 68, 81, 83
9
Pintore (2013) GTKO/CD55/CD59/CD39
Cynomolgus 
monkey (n=5)
CyP, CsA, MMF, CS 18 +/- 3.2 (16)
GTKO/CD55/CD59/CD39/HT
Cynomolgus 
monkey (n=3)
Anti-CD20mAb, CsA, MMF, CS 13 +/- 2.3 (12)
10
Spiezia (2013) GTKO/CD55
Cynomolgous 
monkey (n=2)
CyP or anti-CD20mAb, CsA, MMF, CS 12, 13
GTKO/CD55/CD59/CD39/HT
Cynomolgus 
monkey (n=2)
CyP or anti-CD20mAb, CsA, MMF, CS 8, 8
11
Ezzelarab (2014) GTKO Baboon (n=1) Anti-CD154mAb, ATG, MMF 6
GTKO/CD46 Baboon (n=3) Anti-CD154mAb, ATG, MMF 9, 10, 10
12
Hwang (2014) GTKO (heart and kidney)
Cynomologus 
monkey (n=2)
ATG, anti-CD20mAb, anti-CD154mAb, CVF, tacrolimus, steroid 24, 25
13
Sekijima (2014) GTKO (MGH-Nippon)
Cynomolgus 
monkey (n=3)
splenectomy, ATG, anti-CD20mAb, tacrolimus, MMF, anti-
CD154mAb, prostacyclin, sTBM, ganciclovir
27, 28, 30
GTKO (Meji U)
Cynomolgus 
monkey (n=5)
splenectomy, ATG, anti-CD20mAb, tacrolimus, MMF, anti-
CD154mAb, prostacyclin, sTBM, ganciclovir
7 to 15,  9.2 average
14
Bottino (2014) GTKO Baboon (n=6)
pre-treatment with anti-CD20mAb, (thymokidney) thymectomy, 
splenectomy, ATG, anti-CD2mAb, antiCD154mAb, MMF, CS
average > 12.5
15
Le Bas-Bernardet 
(2015)
GTKO/CD55/CD59/CD39/HT Babon (n= 2) splenectomy 4, 3
GTKO/CD55/CD59/CD39/HT Babon (n= 3) MMF, CS, tacrolimus, CyP (n=2), rhC1-INH 15, 13, 12
GTKO/CD55/CD59/CD39/HT Babon (n= 3)
splenectomy, plasma exchange (d4, 1), MMF, CS, tacrolimus, 
bortezomib, rhC1-INH
9, 9, 11
GTKO/CD55/CD59/CD39/HT Babon (n= 4)
splenectomy, plasma exchange (d4, 1, 3), MMF, CS, tacrolimus, 
bortezomib, rhC1-INH
12, 14, 12, 14
GTKO Babon (n= 1)
splenectomy, plasma exchange (d4, 1, 3), MMF, CS, tacrolimus, 
bortezomib, rhC1-INH
11
anti-CD3IT - anti-CD3 immunotoxin, ATG - anti-thymocyte globulin, BMTx - bone marrow transplant, CS - corticosteroids, CsA - cyclosporine, CVF - cobra venom 
factor, CyP - cyclophosphamide, IS - immunosuppression, mAb - monoclonal antibody, MMF - mycophenolate mofetil, rhC1-INH - recombinant human C1 
inhibitor, sTBM - soluble thrombo modulin, TI - thymic irradiation, TBI - total body irradiation
   Table 2 GTKO kidney xenotransplantation experiments since 2005 
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Table 3 GTKO and record cardiac xenotransplantation experiments since 2005 
 
 
  
First Author (year) Donor genetics Recipient (n) Immunosuppression Survival time in days  (median)
1 McGregor (2005) hCD46 Baboon (n=7)
Splenectomy, ATG, anti-CD20mAb, tacrolimus, 
rapamycin, CS, TPC
15, 38 , 54, 64, 96, 99, 137 (96)
2 Kuwaki (2005) GTKO Baboon (n=8)
ATG, anti-CD2mAB, TI, CVF, anti-CD154mAb, 
MMF, CS
>16, >23, >56, 59, 67, 78, 110, 179 (63)
3 Byrne (2008) GTKO Baboon (n=8)
splenectomy, ATG, anti-CD20mAb, tacrolimus, 
rapamycin
0 to 128 (25)
4 Ezzelarab (2009) GTKO Baboon (n=9) ATG, CVF, anti-CD154mAb, MMF, CS 0, 1, 6, 6, 7, 12, 12, 35, 56 (7)
5 Bauer (2010) GTKO/CD46 Baboon (n=2)
ATG, anti-CD20mAb, tacrolimus, rapamycin, 
MMF, CS, bortezomib, immunoadsorption (n=1)
<1, 50
6 Tazelaar (2011) GTKO +/- CD55 Baboon n=5) ATG, anti-CD20mAb, tacrolimus, rapamycin 18 to 71 (26)
7 Mohiuddin (2012) GTKO/CD46 Baboon (n=2) No IS <1, <1
Baboon (=2) ATG, CVF, anti-CD154mAb, MMf, CS 8, 8
Baboon (n=9)
ATG, anti-CD20mAb, CVF, anti-CD154mAb, MMf, 
CS
>36, >39, >42, >58, > 71, 75, >115, >179, 
>236 (71)
8 McGregor (2012) GTKO Baboon (n=6) ATG, anti-CD20mAb, tacrolimus, rapamycin, CS 0, 2, 21, 22, 79, 128 (21)
GTKO/CD55 Baboon (n=5) ATG, anti-CD20mAb, tacrolimus, rapamycin, CS 15, 27, 28, 41, 52 (28)
9 Kim (2013) GTKO
Cynomologus 
monkey (n=4)
ATG, anti-CD20mAb, CVF, anti-CD154mAb, 
tacrolimus, CS
11, 14, 14, 24 (14)
10 Mohiuddin (2013) GTKO/CD46 Baboon (n=3)
ATG, anti-CD20mAb, CVF, anti-CD40mAb (3A4), 
MMF, CS
21, 21, 28 (21)
Baboon (n=6)
ATG, anti-CD20mAb, CVF, anti-CD40mAb 
(2C10R4), MMF, CS
>30, >40, 60,107,146, 149 (84)
11 Mohiuddin (2014) GTKO/CD46/TBM Baboon (n=5)
ATG, anti-CD20mAb, CVF, anti-CD40mAb (2C10), 
MMF, CS, steroids
146, 159, >200, >380, >500 [3 ongoing 
>200 to > 500 days](>200)
12 Ezzelarab (2014) GTKO Baboon (n=2) Anti-CD154mAb, ATG, MMF 56, 35
GTKO/CD46 Baboon (n=1) Anti-CD154mAb, ATG, MMF 26
13 Hwang (2014) GTKO (heart and kidney)
Cynomologus 
monkey (n=2)
ATG, anti-CD20mAb, anti-CD154mAb, CVF, 
tacrolimus, steroid
24, 25
A Byrne (2011) CD46 or CD55 or GTKO/CD55
Baboon (n=14) non 
life supporting
ATG or Cyp, tacrolimus, rapamycin +/- anti-
CD20mAb +/- GAS914 or TPC
0 to 57 (6)
ATG - anti-thymocyte globulin, CS - cyclosporine, CVF - cobra venom factor, IS - immunosuppression, mAb - monoclonal antibody, MMF - mycophenolate mofetil
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Preamble 
As demonstrated above, the impact of antibodies elicited against GTKO 
xenografts cannot be overstated. Currently, most xenotransplantation laboratories favor 
inhibition of the majority of the adaptive antibody response utilizing a combination of B 
cell depletion and inhibition of T cell-mediated B cell activation (costimulation 
blockade). Unfortunately, while therapies such as these, which indiscriminately disarm B 
cells, can significantly prolong xenograft survival (6, 34, 92), they also significantly 
heighten recipient susceptibility to infectious complications (35-37). More selective 
inhibition of the anti-non-Gal antibody response may enhance xenograft survival while 
preserving a greater portion of B cell-mediated adaptive immunity to ward off infection. 
The following chapters describe original research which provides further molecular 
characterization of antibodies elicited by xenotransplantation in addition to identification 
of small molecules capable of selectively inhibiting antibodies elicited by 
xenotransplantation. 
 
Chapter 2 - Rationale and Hypothesis 
Our collaborators at St. Vincent’s hospital in Melbourne have generated GTKO 
pigs expressing the human transgenes CD55, CD59, and HT 
(GTKO/hCD55.hCD59.hHT)(16, 72, 94). In addition to human complement regulatory 
proteins (CD55 and CD59), these animals express the enzyme α-1,2-fucosyltransferase 
(H-transferase, HT). This modification has been thought to reduce the immunogenicity of 
the graft glycocalyx by reducing surface expression of immunogenic terminal 
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carbohydrates by replacing them with the immunologically inert terminal α-1,2-fucose 
(human blood group O antigen) (95). 
Porcine neonatal islet cell clusters from these animals have been isolated and 
transplanted into baboons (Papio hamadryas) at Westmead laboratories. Baboons were 
treated with a typical allotransplantation immunosuppressive protocol. However, the 
presence of a strong anti-non-Gal antibody response (85)(see chapter 2), as reported in 
other GTKO islet xenotransplantation experiments (96), provided the opportunity to 
analyze the heavy and light chain usage in GTKO xenoislet transplantation. We have 
previously identified the antibody heavy chain elicited against GTKO pig endothelial 
cells (33). However, amino acid residues which contribute to the binding site of anti-non-
Gal antibodies are likely to be conserved between settings. We hypothesized that the 
baboon antibody response elicited against GTKO/hCD55.hCD59.hHT porcine islets 
would be encoded by genes which would demonstrate a high degree of sequence and 
modeled structural homology with previously identified primate anti-pig antibodies.  
This chapter provided three key pieces of information which prompted additional 
inquiry outlined in chapters three and four: 1) the antibody response to GTKO pig islets, 
like that to GTKO pig endothelial cells (33), is primarily composed of antibodies which 
have a high degree of sequence, and modeled structural homology; 2) the heavy chain 
elicited against porcine islets has a high degree of sequence, and modeled structural 
homology with the antibody heavy chain elicited against pig endothelial cells; and 3) 
both of the heavy chain genes which encode these elicited antibodies also encode human 
antibodies which inhibit the function of clotting factor VIII. 
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Chapter 3 – Rationale and Hypothesis 
Endothelial cells are known to express several of the currently known non-Gal 
porcine antigens (52, 53, 97). FVIII is also known to be synthesized and released by 
endothelial cells in the dermis, aorta, heart, lung, liver, and kidney (98-100). As noted 
above, our lab has previously intravenously injected rhesus monkeys with GTKO porcine 
aortic endothelial cells to stimulate an anti-non-Gal antibody response without the 
procedural complications of islet or solid organ xenotransplantation (101). Our 
preliminary data demonstrated that the elicited antibodies inhibit FVIII cofactor activity 
significantly more than those present before immunization (see chapter 3). Of interest, 
this level of inhibition is consistent with an inhibitor titer of approximately 16 Bethesda 
units (Bu); where an increase in 5 Bu in humans can indicate pathology (102). However, 
the “normal” coagulation parameters after xenotransplantation are currently under 
investigation (103, 104). 
On occasion, acquisition of FVIII inhibitors has been traced to the mutation of a 
single amino acid of FVIII (105-107). Of note, there is only 76-90% amino acid 
homology between porcine and human FVIII for those domains commonly inhibited 
(108). Characterization of the antibody-FVIII interactions that are likely to participate in 
antibody-mediated injury after xenotransplantation of genetically modified porcine cells 
and organs should enhance our ability to rationally design methods directed at mitigating 
humoral rejection. We hypothesized that elicited anti-pig antibody would inhibit 
cofactor activity of FVIII by binding to domain segments which are not homologous 
between pigs and primates. 
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Chapter 4 – Rationale and Hypothesis 
While selective inhibition of anti-non-Gal antibodies may at first seem to be a tall 
order, work from our lab published in 2008 demonstrated its plausibility (33). We 
determined that the heavy chain of anti-non-Gal antibodies elicited by rhesus monkeys 
against GTKO pig endothelial cells is encoded by a germline gene most similar to the 
human gene IGHV3-21. Furthermore, 72-85% of antibody-producing peripheral blood 
mononuclear cells utilized this gene by 8 days after immunization compared with 1-3% 
on day 0. Thus, therapies which target antibodies encoded by this gene could 
preemptively inhibit at least 72-85% of the anti-non-Gal xenoantibody response. The 
spirit of this approach is comparable to several methods previously utilized to inhibit 
anti-Gal antibody-mediated hyperacute rejection (39). These methods utilized structural 
derivatives of the Gal carbohydrate to selectively inhibit anti-Gal antibodies. These 
treatment modalities had varying levels of success (74, 75, 109) and went out of favor 
with the production of GTKO pigs. However, unlike anti-Gal antibodies, antibodies 
against non-Gal pig antigens pre-exist at low levels (32, 33) and do not initiate rejection 
until after the initiation of a vigorous humoral response (22, 24, 110). Therefore, 
selectively, and preemptively, disrupting the B cell receptor (antibody)-antigen 
interaction would inhibit the formation of a productive B cell response and antibody-
mediated rejection of GTKO porcine cells and organs. To our knowledge, small 
molecules which can selectively inhibit anti-non-Gal antibodies have not been reported 
by others. We hypothesized that the combination of screening a clinically relevant 
small molecule library in silico and in vitro would allow us to identify drugs which 
selectively inhibit elicited anti-non-Gal antibodies.  
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Abstract 
Background: Promising developments in porcine islet xenotransplantation could 
resolve the donor pancreas shortage for type 1 diabetic patients. Using GTKO donor pigs 
with multiple transgenes should extend xenoislet survival via reducing complement 
activation, thrombus formation, and the requirement for exogenous immune suppression. 
Studying the xenoantibody response to GTKO/hCD55/hCD59/hHT islets in the pig-to-
baboon model, and comparing it with previously analyzed responses, would allow the 
development of inhibitory reagents capable of targeting conserved idiotypic regions.  
Methods: We generated IgM heavy and light chain gene libraries from ten 
untreated baboons and three baboons at 28 days following transplantation of 
GTKO/hCD55/hCD59/hHT pig neonatal islet cell clusters with immunosuppression. 
Flow cytometry was used to confirm the induction of a xenoantibody response. IgM 
germline gene usage was compared pre and post transplant. Homology modeling was 
used to compare the structure of xenoantibodies elicited after transplantation of 
GTKO/hCD55/hCD59/hHT pig islets with those induced by GTKO and wild type pig 
endothelial cells without further genetic modification. 
Results: IgM xenoantibodies that bind to GTKO pig cells and wild type pig cells 
were induced after transplantation. These anti-nonGal antibodies were encoded by the 
IGHV3-66*02 (Δ28%) and IGKV1-12*02 (Δ25%) alleles, for the immunoglobulin heavy 
and light chains, respectively. IGHV3-66 is 86.7% similar to IGHV3-21 which was 
elicited by rhesus monkeys in response to GTKO endothelial cells. Heavy chain genes 
most similar to IGHV3-66 were found to utilize the IGHJ4 gene in 85% of V-D regions 
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analyzed. However, unlike the wild type response, a consensus complementarity 
determining region 3 was not identified.  
Conclusions: Additional genetic modifications in transgenic GTKO pigs do not 
substantially modify the structure of the restricted group of anti-nonGal xenoantibodies 
that mediate induced xenoantibody responses with or without immunosuppression.  The 
use of this information to develop new therapeutic agents to target this restricted response 
will likely be beneficial for long term islet cell survival and for developing targeted 
immunosuppressive regimens with less toxicity. 
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Introduction 
Allotransplantation has provided an effective treatment for patients with type 1 
diabetes (T1D) and its debilitating chronic complications [1, 2]. Due to the current 
shortage of donor pancreatic islets, however, transplantation of porcine islets is being 
considered as a potential alternative [3-6]. Survival for over 1 yr with diabetes reversal 
has now been reported in diabetic non-human primates (NHPs) using porcine islets in 
combination with chronic immunosuppression [3, 4, 6]. 
Immune-mediated rejection remains a challenge to the survival of genetically 
modified porcine xenografts [5-9]. In preclinical studies, various immunosuppressive 
regimens have been developed to facilitate porcine to primate islet cell transplants, but 
the most successful regimens represent an immunosuppressive burden that is greater than 
that currently used in human allotransplantation [7, 10-12]. The use of α1,3-
galactosyltransferase gene knockout (GTKO) neonatal porcine islets reduces the immune 
response and improves the rate of return to normoglycemia [5]. Genetic modifications 
such as the expression of human complement regulatory proteins, hCD55, and hCD59 in 
transgenic pig donors reduce the rate of complement activation [6, 13-15], and the 
introduction of additional transgenes may make it feasible to further prolong graft 
survival. Nevertheless, genetic modification alone is not likely to be sufficient to mitigate 
rejection given the profound immune barrier existing between the human and pig species. 
Combination therapies, including those that are directed at xenoantibodies, will need to 
be developed to improve xenograft survival beyond what is currently achievable using 
existing strategies. 
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Our laboratory has defined a selected, restricted usage of immunoglobulin heavy 
chain variable (IGHV) and immunoglobulin kappa light chain variable (IGKV) genes that 
encode xenoantibodies in multiple settings [16-19]. Although we have previously 
identified the IGHV utilized in response to GTKO endothelial cells in non-
immunosuppressed rhesus monkeys, this report identifies both the immunoglobulin (Ig) 
heavy and light chain genes that encode the xenoantibodies induced in baboons 
responding to transplantation with GTKO/hCD55/hCD59/hHT transgenic porcine 
neonatal islet cell clusters (NICC). Amino acid residues which contribute the binding site 
of anti-non-Gal xenoantibodies are likely to be conserved between systems. Thus, the 
goal of our study was to identify the structure of xenoantibodies that initiate antibody-
mediated injury after genetically modified porcine islet cell xenotransplantation, to 
compare these with previously identified antibody sequences, and ultimately to use this 
information to rationally design selective immunosuppressive interventions directed at 
mitigating humoral rejection. 
 
Materials and Methods 
Preparation of cDNA libraries and analysis of immunoglobulin gene usage 
α1,3-Galactosyltransferase gene knockout donor pigs (Sus scrofa) transgenic for 
hCD55, hCD59, and hHT were generated by Cowan et al. [8, 13, 14], and porcine NICC 
from these animals were produced and transplanted (10 000 IEQ/kg) into baboons (Papio 
hamadryas) at the Westmead laboratories. Prior to NICC isolation and transplantation, 
expression of Gal, CD55, and CD59 on peripheral blood leukocytes from 
GTKO/hCD55/hCD59/hHT was analyzed by flow cytometry (Fig. 1) as previously 
 42 
described [13] with the exception that Gal expression was detected using a fluorescein 
isothiocyanate (FITC)-conjugated anti-Gal monoclonal antibody (GT6-27-23) which was 
prepared from a hybridoma kindly provided by Dr. Guerard Byrne, Nextran, Princeton 
NJ, USA. 
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Figure 1.  Flow cytometric analysis of transgene expression of peripheral blood from 
a GTKO/hCD55/hCD59/hHTF pig (black), compared with a wild type non transgenic 
pig (white). GTKO/hCD55/hCD59/hHTF pigs do not express α Gal and strongly 
express human CD55 and human CD59. 
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Baboons were treated with a typical allotransplant immunosuppressive protocol, 
including a combination of induction with anti-thymocyte globulin (ATG) and ongoing 
treatment with mycophenolate mofetil and tacrolimus. However, because antibodies 
developed after transplantation, we sought the opportunity to analyze this response. 
Serum and peripheral blood cell samples from a total of 10 baboons were used to prepare 
cDNA libraries for the analysis of the immune repertoire in control and transplanted 
animals. cDNA libraries representing genes encoding xenoantibodies before and after 
transplantation were constructed as previously described [16]. Nested PCRs were 
performed to amplify the product of somatic recombination of either the heavy chain V, 
D, and J antibody gene progenitors or the light chain V and J antibody gene progenitors 
[17-20]. Ig heavy chain libraries were prepared by amplifying cDNA using a μ-chain-
specific primer (Cμ; 5′-GGG AAA AGG GTT GGG GCG GAT GCA-3′) and a 
framework region (FWR) specific primer for the IGHV 3 family (VH3; 5′-GAG GTG 
CAG CTG GTG GAG TCT GG-3′). The first PCR for the IgM libraries was then 
subjected to one additional nested reaction. VH primer (5′-TCT GGG GGA GGC TTG 
GTC-3′) and Cμ primer pairs were used in the nested PCR. The primers used to amplify 
immunoglobulin kappa light chain genes were kappa 5 (5′-CAG ATG GCG GGA AGA 
TGA AG-3′) and CR50 (5′-AGC TCC TGG GGC T(GC) CT(AG)(AC) TGC-3′), which 
is aligned to the FWR1 of the light chain. The first nested PCR was performed using the 
CR50 and kappa 4 (5′-ACA GAT GGT GCA GCC ACA G-3′) primers. The second 
nested PCR was amplified using kappa 4 paired with the primer (5′-TCT GCA TCT GTA 
GGA GAC-3′). The PCR was performed in a TECHNE TC-4000 PCR System 
Thermocycler (Bibby Scientific Limited, Staffordshire, UK) for one cycle of 94 °C 5 min 
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followed by 35 cycles of 94 °C for 30 s, 53 °C for 30 s, 72 °C for 60 s and one cycle of 
72 °C for 7 min. The PCR products were verified by size on a 2% agarose gel, cloned 
into the TA 2.1 vector (Invitrogen, Carlsbad, CA, USA), transformed into MAX 
Efficiency DH5α™ T1R competent cells (Invitrogen); DNA was isolated, and the clones 
were sequenced by the City of Hope DNA sequencing core facility. A minimum of 40 
heavy and 40 light chain sequences were obtained per transplanted animal. Sequencing 
results were analyzed using the NCBI website (http://0-
www.ncbi.nlm.nih.gov.catalog.llu.edu/igblast/) to identify the closest human germline 
progenitor genes. Pre- and post-transplant Ig gene usage was compared in each animal 
and in a series of control animals, allowing us to define the normal repertoire of Ig gene 
usage in baboons and to identify changes in the relative frequency of usage of specific 
IGHV and IGKV genes. 
 
Flow Cytometry 
Xenoantibody levels in the sera of recipient baboons were determined at 28 days 
after transplantation of genetically modified porcine NICC. Heat-inactivated baboon 
serum samples were diluted 1/10 and were incubated at room temperature with 
endothelial cells from both GTKO and wild-type pigs. Cells were washed twice with cold 
FACS buffer and incubated with FITC-conjugated goat (Fab') anti-human IgM (Southern 
Biotech, Birmingham, AL, USA) or FITC-conjugated goat anti-human IgG (γ-chain 
specific) (Sigma, St. Louis, MO, USA). The cells were washed, resuspended in cold 
FACS buffer, and analyzed on a FACSCalibur flow cytometer (Becton Dickinson, San 
Diego, CA, USA) using FlowJo software (Tree stars, Ashland, OR, USA). 
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Homology Modeling 
Homology modeling, along with further in silico refinement, was used to compare 
post-transplant anti-non-Gal xenoantibodies induced by rhesus monkeys in response to 
GTKO pig endothelial cells without additional genetic modifications [19] and by baboons 
in response to GTKO/hCD55/hCD59/hHT porcine islets. Antibody models were prepared 
using the Discovery Studio 3.5 software suite (Accelrys, San Diego, CA, USA) using 
representative sequences derived from post-transplant IgM xenoantibodies. Each 
antibody FWR was modeled based on homology using Modeller and crystal structures 
deposited in the Protein Data Bank (RCSB.org). Antibody complementarity determining 
regions (CDRs) were modeled separately using the three crystal structures with the 
highest degree of sequence homology available for each CDR. Ab initio structural 
refinement and molecular dynamic simulations were used to optimize prediction of the 
heavy chain CDR3 which had the lowest percent homology in each case. For visual 
comparison, heavy chain models were aligned by the α-carbons and colored by amino 
acid. 
 
Results 
Immunoglobulin heavy and light chain gene usage in untreated baboons 
The distribution of heavy and kappa light chain Ig germline gene usage in 10 
untreated baboons including the three recipient animals was analyzed to identify normal 
variability within the baboon colony (Fig. 2). The Ig heavy chain gene that was used most 
frequently in untreated baboons most closely resembled human IGHV3-23. The light 
chain genes used most frequently were most similar to human IGKV1D-16 and IGKV1-9 
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germline progenitors. There is little information currently available reporting the 
sequence of baboon germline genes; however, in our experience, the sequences encoding 
immunoglobulin genes in baboons are very similar to human immunoglobulin gene 
sequences. 
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Figure 2. The frequency of IGHV3 and IGKV gene usage in untreated baboons. (A) 
The IGHV3-23 germline gene is most frequently utilized in the normal baboon 
repertoire.  The distribution of IGHV3 germline gene usage was determined by 
sequencing IGHV3 family genes in ten untreated baboons including 3 which later 
received transplants. (B) IgKV germline gene usage in untreated baboons was 
determined by sequencing immunoglobulin light chain gene libraries in ten  baboons. 
The IGKV1D-16 and IGKV1-9 germline genes were most frequently used in these 
animals. Data is represented as average usage per animal ± the standard error of the 
mean.  N= the number of colonies sequenced. 
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Restricted Xenoantibody Response to Porcine Islet Transplantation 
At 28 days after transgenic porcine NICC transplantation, we observed a >2-fold 
increase in the usage of the IGKV1-12*02 and IGHV3-66*02 light and heavy chain 
genes relative to pre-transplant levels (Fig. 3A). Both pre- and post-transplant levels were 
determined independently in each baboon. The results were consistent in all animals. 
Figure 3 shows representative cDNA sequences from libraries that were prepared pre- 
and post-transplantation. The germline gene used most frequently to encode 
xenoantibodies in this model was IGHV3-66, a gene that is closely related but not 
identical to IGHV3-21, and the germline progenitor that encodes xenoantibodies elicited 
by non-immunosuppressed rhesus monkeys after immunization with GTKO pig 
endothelial cells without additional genetic modifications. The similarity in the Ig gene 
sequence when comparing xenoantibodies to GTKO islet cells and IGHV3-21 is shown 
in Fig. 3B,C. These genes are 86.7% similar at the amino acid level. The xenoantibodies 
induced in response to transplantation of genetically modified porcine islets are also 
92.0% similar to the human IGHV3-11*01 allele encoding human xenoantibodies to 
wild-type pig solid organs or islet cells [17].  
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A 
 
 
 
 
B             <--------------------------------------FWR1--------------------------- 
IGHV3-21*01    GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGATTCTCCTGTGCAG 
H.11           ------------------------------T-----C--------------------C------------                                                           
H.13           ------------------------------T-----C--------------------C------------ 
H.18           ------------------------------T-----C--------------------C------------ 
H.19           ------------------------------T-----C--------------------C------------ 
 
               -------------------><-----CDR1----><-------------------FWR2----------- 
IGHV3-21*01    CCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTG 
H.11           -------------------------CTA-----G------------------------------------ 
H.13           -------------------------CTA-----G------------------------------------ 
H.18           -------------------------CTA-----G------------------------------------ 
H.19           -------------------------CTA-----G------------------------------------ 
     
               ------>  <-------------------------CDR2--------------------> <-------- 
IGHV3-21*01    GGTCTCA  TCCATTAGTAGTAGTAGTAGTTACATATACTACGCAGACTCAGTGAAGGGC CGATTCACC 
H.11           -------  -A----...------G—-G—-AG—-C---------------C--------- --------- 
H.13           -------  -A----...------G—-G—-AG—-C---------------C--------- --------- 
H.18           -------  -A----...------G—-G—-AG—-C---------------C--------- --------- 
H.19           -------  -A----...------G—-G—-AG—-C---------------C--------- --------- 
  
               --------------------------------------FWR3---------------------------- 
IGHV3-21*01    ATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTG 
H.11           ---------------T-A------A-G—-C-CC------------------------------------- 
H.13           ---------------T-A------A-G—-C-CC------------------------------------- 
H.18           ---------------T-A------A-G—-C-CC------------------------------------- 
H.19           ---------------T-A-G----A-G—-C-CC-------------------------------------  
               
               ----------------> 
IGHV3-21*01    TGTATTACTGTGCGAGA 
H.11           -C—-C------------ 
H.13           -C—-C------------ 
H.18           -C—-C------------ 
H.19           -C--------------- 
 
C                          FWR1       CDR1         FWR2 
                             25  30      35      40   45 
                             |    |       |       |    |       
HumanIGHV3-21*01         SCAASGFTFS   SYYMN   WVRQAPGKGLEWVS 
Pretransplant            ----------   ----S   --------A----- 
Posttransplant           ----------   ----S   --------A----- 
 
                             CDR2                   FWR3 
                         50    55   60  65      70    75   80  85   90  95   
                         |     |    |    |       |    |    |    |    |   |    
HumanIGHV3-21*01         SISSSSSTIYYADSVKG   RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR 
Pretransplant            Y-.--GGST--------   --------S—-T-S------------------ 
Posttransplant           Y-.--GGST--------   --------S—-T-S------------------ 
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Figure 3. The anti-nonGal xenoantibody response to genetically modified porcine islets 
is restricted. (A) The usage of the immunoglobulin heavy chain gene IGHV3-66*02 was 
elevated from 7%+0% in pretransplant baboon serum to 35% ±6% post-islet cell 
transplantation. (B) The nucleotide sequence of four representative IGHV genes 
encoding IgM anti-nonGal xenoantibodies is shown.  The IGHV genes encoding anti-
nonGal porcine islet xenoantibodies is shown compared to the sequence of the IGHV3-
21*01 germline gene which encodes anti-nonGal xenoantibodies to GTKO pig 
endothelial cells without multiple genetic modifications. (C) The amino acid sequence 
of IGHV genes encoding anti-nonGal xenoantibodies to genetically modified pig islets 
is shown. The regions of the CDR1 and CDR2 which are conserved may be relevant for 
contact with nonGal xenoantigen. (-) Identical residues when compared with the closest 
human germline gene. FWR (framework region) CDR (complementarity determining 
region). 
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The light chain gene encoding xenoantibodies to either wild-type or genetically 
modified GTKO cells is identical [21]. Representative amino acid sequences from pre-
transplant and post-transplant samples are shown aligned to human IGKV1-12*02 
(IGKV1D-12*02) (Fig. 4). As demonstrated by flow cytometry in Fig. 5, induced 
xenoantibodies present in the serum at 28 days after transplantation with genetically 
modified GTKO porcine islets also bind to wild-type pig cells. The fact that the response 
induced by NICC transplantation can be measured using endothelial cells indicates there 
is likely a prominent common non-Gal antigen expressed on both of these cell types. 
Furthermore, the high degree of sequence similarity in the induced xenoantibodies that 
bind Gal and non-Gal targets supports the concept of an induced, structurally related 
xenoantibody response initiated after pig cell xenotransplantation. 
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B           <-------------FWR1-------------------->   <--------------CDR1-------------> 
IGKV1-12*02  CTTTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGT CGGGCGAGTCAGGGTATTAGCAGCTGGTTAGCC 
K.2        ----------------------A---------------C -AT—-C--------------------------- 
K.7          ----------------------A---------------C  -AT--C--------------------------- 
K.10       ----------------------A---------------C -AT--C--------------------------- 
K.12         ----------------------A---------------C -AT--C--------------------------G 
 
            <---------------------FWR2------------------>  <--------CDR2------->  <---- 
IGKV1-12*02  TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTAT  GCTGCATCCAGTTTGCAAAGT  GGGGT 
K. 2        ---------------------------------------------  AAG------------------  ----- 
K. 7       ---------------------------------------------  AAG------------------  ----- 
K.10       ---------------------------------------------  AAG------------------  ----- 
K.12       ---------------------------------------------  AAG------------------  ----- 
 
            <--------------------------------FWR3-------------------------------------> 
IGKV1-12*02 CCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTT 
K. 2        ------------------------------A-------------------------------------------- 
K. 7       ------------------------------A-------------------------------------------- 
K.10       ------------------------------A-------------------------------------------- 
K.12       ------------------------------------A----------------C-------------------G- 
 
            ---------------> 
IGKV1-12*02 TGCAACTTACTATTGT 
K. 2      ----G----T--C--- 
K. 7       ---------T--C--- 
K.10       ---------T—-C--- 
K.12       ---------T—-C--- 
 
 
C                           FWR1            CDR1          FWR2 
                            15    20      25  30        35   40   45 
                             |    |       |    |        |    |    |     
IGKV1-12*02               SASVGDRVTITC   RASQGISSWLA    WYQQKPGKAPKLLIY 
Pretransplant             ------K-----   H----------    --------------- 
Posttransplant            ------K-----   H----------    --------------- 
                                                  
 
                            CDR2         FWR3 
                          50   55      60   65  70   75   80   85     
                          |    |       |    |    |    |    |    |     
IGKV1-12*02               AASSLQS   GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC  
Pretransplant             K------   --------------------------------  
Posttransplant            K------   -------------------------------- 
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Figure 4. The immunoglobulin light chain germline genes encoding anti-nonGal 
xenoantibodies and anti-gal xenoantibodies is identical (A) The usage of the IGKV1-
12*02 germline gene was 11%+6% in pre-transplant serum and 36%+5% in post-
transplant serum. (B) The nucleotide sequence of four representative IGKV genes 
encoding IgM xenoantibodies following porcine islet transplantation is shown compared 
to the closest human progenitor, the IGKV1-12*02 germline gene. (C) The amino acid 
sequence of representative pre and post-transplant samples is shown aligned with the 
amino acid sequence of the human IGKV1-12*02 gene. The residues which contribute 
to the gal carbohydrate binding sites of anti-gal xenoantibody are reported in ref (20). 
Many of these sites are conserved on both the heavy and light chain suggesting anti-
nonGal and anti-gal xenoantibodies may have similar antibody-antigen interactions. (-
)Identical residues when compared with the closest human germline gene. FWR 
(framework region) CDR (complementarity determining region). 
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Figure 5. Xenoantibody responses pre (white) and 28 days post (black) transplantation 
in the sera of three baboons (i, ii, iii) which received genetically modified GTKO porcine 
islets. Induced IgM (A&B) and IgG (C&D) xenoantibodies bind to (A&C) wild type 
pig (1.4-8.5 fold increase in Mean Fluorescence Intensity or MFI)and (B&D) GTKO 
pig endothelial cells (1.7-5.5 fold increase in MFI). 
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J Segment Usage 
A restricted usage of heavy chain joining (IGHJ) genes was noted when 
comparing post-transplant cDNA libraries with those prepared from pre-transplant 
animals. A diverse selection of immunoglobulin kappa joining (IGKJ) genes was 
represented pre-transplant. The IGHJ4*02 allele accounted for 85% of J segment usage in 
40 sequenced cDNA samples per animal examined with a functional IGHV gene (Fig. 6). 
Heavy chain genes most similar to the human IGHV3-66*2 germline gene were found to 
utilize the IGHJ4*02 allele in 85% of V-D regions analyzed. However, unlike the heavy 
chain utilized in response to wild-type pig solid organs or islet cells [17], our analysis of 
the encoded antibody sequences indicates that there is no consensus CDR3 amino acid 
sequence utilized in the anti-non-Gal xenoantibody response. 
 
Comparison of Heavy Chain Structure in GTKO Xenotransplantation 
There is predicted to be a high degree of structural homology between the heavy 
chains utilized in the xenoantibody responses of rhesus monkeys responding against 
GTKO endothelial cells [19] and baboons responding against GTKO/hCD55/hCD59/hHT 
transgenic porcine islets (Fig. 7). Within the heavy chain variable region, the CDR1 
segments are nearly identical (Fig. 7B), while only moderate differences exist when 
comparing the CDR2 segments (Fig. 7C). No structural homology is evident when 
comparing the CDR3 segments (Fig. 7D). Thus, amino acid residues which are conserved 
are likely to make contact with a common antigen. 
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Figure 6. Immunoglobulin J gene usage following islet cell cluster transplantation in 
baboons.  The IGHJ gene usage was restricted to IGHJ4*02 in all baboons after porcine 
islet cell transplantation (87%+2%). 
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Figure 7. Structural alignment of modeled anti-non gal heavy chain antibodies – 
Structural alignment of modeled xenoantibody heavy chains associated with the 
immune response induced by GTKO endothelial cells (orange) and GTKO islet cells 
(black). Residues which are not conserved are highlighted in green on both heavy 
chains. The high degree of structural similarity suggests conserved amino acids likely 
make contact with xenoantigen. (A) Complementarity determining regions (CDRs) are 
depicted together. For emphasis, the (B) CDR1, (C) CDR2, and (D) CDR3 are depicted 
individually. The CDR1 and CDR2 display a high degree of structural similarity. In 
contrast, the CDR3 does not display this structural similarity. GTKO islet associated 
CDR3; GTKO endothelial cell associated CDR3. Alignment is by the α-carbon. 
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Discussion 
Our study has demonstrated that the IGHV genes encoding the restricted 
xenoantibody response to GTKO/hCD55/hCD59/hHT transgenic islets in the pig-to-
baboon model are closely related, but not identical, to IGHV genes encoding the induced 
xenoantibody response to GTKO endothelial cells without further transgenic 
modification. A restricted usage of IGHJ4*02 was noted in both models; however, the 
amino acid sequence of the CDR3 segment was not conserved as shown by both 
sequence analysis and modeling. The light chain genes encoding xenoantibodies, in 
contrast, are identical when comparing induced xenoantibodies responding to GTKO pig 
cells or wild-type pig cells. 
The development of GTKO pigs has played an important role in reducing the 
xenoantibody response after xenograft transplantation [5, 22, 23]. Xenotransplantation 
using GTKO donors abrogates hyperacute rejection, significantly extending heart 
survival [22], and resulting in the rapid return of euglycemia [5] after pig heart and islet 
transplantation in baboons, respectively. The more recent generation of GTKO pigs with 
additional genetic modifications improves xenograft survival in cardiac models [15] and 
reduces early islet loss as well [6]. 
A significant xenoantibody response is induced at 28 days after transplantation of 
genetically modified GTKO porcine NICC while under immunosuppression. This finding 
is consistent with recent data from the Kirk laboratory using Gal-deficient pig neonatal 
islets [5]. Transplantation of Gal-deficient islets improves the rate of achieving insulin 
independence in diabetic NHP, but rejection is not prevented. Elimination of anti-non-
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Gal xenoantibodies may be required to prolong graft survival after porcine islet cell 
cluster xenotransplantation. 
We report here that specific heavy (IGHV3-66) and light chain (IGKV1-12) gene 
usage was elevated 28% in baboons after transplantation with porcine islet cell clusters. 
These antibodies preexist in the immune repertoire of baboons, albeit at relatively low 
levels. Monoclonal antibodies encoded by the IGHV3-66*01 can react to a highly 
conserved influenza A virus epitope [24], and interestingly, both the IGHV3-21 and 
IGHV3-66 heavy chain IGHV genes in germline formation can contribute to the 
production of antibodies which inhibit clotting factor VIII in patients with hemophilia A 
[25]. It is currently unknown whether the immune response contributes to coagulative 
dysfunction in xenotransplantation and further investigation is warranted. 
Moderate differences that were identified when comparing the IGHV genes 
encoding antibodies elicited by GTKO/hCD55/hCD59/hHT transgenic islet cells 
compared to GTKO pig endothelial cells could be due to a difference in the epitopes 
expressed. It is also possible that the additional genetic modifications may have mildly 
influenced the surface antigenicity of the transplanted pig cells. Alternatively, subtle 
differences between rhesus monkey and baboon IGHV genes encoding immune 
responses could account for these minor differences in IGHV gene usage. Structural 
analysis indicates that within the heavy chain, the CDR1 sequences of Ig genes encoding 
anti-non-Gal and anti-Gal xenoantibodies are highly conserved [19, 20, 22, 26]. In 
contrast, the heavy chain CDR2 segment of anti-non-Gal xenoantibodies demonstrates 
mild variability, while the CDR3 segment demonstrates no similarity. Those regions 
which are structurally preserved are more likely to make contact with the relevant non-
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Gal xenoantigen(s). Designing reagents which target these regions may be a promising 
strategy for interfering with antibody–antigen interactions. 
In conclusion, this is the first study to identify the immunoglobulin genes 
encoding the xenoantibody response following transplantation of 
GTKO/hCD55/hCD59/hHT transgenic pig islets to baboons. Grafts stemming from 
different cell types, tissues, or organs induce a restricted anti-non-Gal xenoantibody 
response encoded by a small group of structurally restricted immunoglobulin gene 
progenitors. Potent immunosuppressive regimens may be substantially reduced in pig 
islet xenotransplantation by blocking these initial IgM responses in a targeted fashion 
using anti-idiotypic antibodies or small molecular inhibitors selective for these 
antibodies. 
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Abstract 
 
Background: Xenotransplantation of porcine organs holds promise of solving the 
human organ donor shortage. The use of α-1,3-galactosyltransferase knockout (GTKO) 
pig donors mitigates hyperacute rejection, while delayed rejection is currently 
precipitated by potent immune and hemostatic complications. Previous analysis by our 
laboratory suggests that clotting factor VIII (FVIII) inhibitors might be elicited by the 
structurally restricted xenoantibody response which occurs after transplantation of either 
pig GTKO/hCD55/hCD59/hHT transgenic neonatal islet cell clusters or GTKO 
endothelial cells. 
Methods: A recombinant xenoantibody was generated using sequences from 
baboons demonstrating an active xenoantibody response at day 28 after 
GTKO/hCD55/hCD59/hHT transgenic pig neonatal islet cell cluster transplantation. 
Rhesus monkeys were immunized with GTKO pig endothelial cells to stimulate an anti-
non-Gal xenoantibody response. Serum was collected at days 0 and 7 after immunization. 
A two-stage chromogenic assay was used to measure FVIII cofactor activity and identify 
antibodies which inhibit FVIII function. Molecular modeling and molecular dynamics 
simulations were used to predict antibody structure and the residues which contribute to 
antibody-FVIII interactions. Competition ELISA was used to verify predictions at the 
domain structural level. 
Results: Antibodies that inhibit recombinant human FVIII function are elicited 
after non-human primates are transplanted with either GTKO pig neonatal islet cell 
clusters or endothelial cells. There is an apparent increase in inhibitor titer by 15 
Bethesda units (Bu) after transplant, where an increase greater than 5 Bu can indicate 
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pathology in humans. Furthermore, competition ELISA verifies the computer modeled 
prediction that the recombinant xenoantibody, H66K12, binds the C1 domain of FVIII. 
Conclusions: The development of FVIII inhibitors is a novel illustration of the 
potential impact the humoral immune response can have on coagulative dysfunction in 
xenotransplantation. However, the contribution of these antibodies to rejection pathology 
requires further evaluation because “normal” coagulation parameters after successful 
xenotransplantation are not fully understood. 
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Introduction 
Delayed xenograft rejection of genetically modified porcine organs is a 
complicated process characterized by vascular antibody deposition, complement 
activation, hemostatic dysregulation, and potent innate and adaptive immune responses 
[1-4]. It is currently unknown whether coagulative dysfunction is, at least in part, 
dependent on the antigraft immune response. The specific importance of the humoral 
immune system in delayed xenograft rejection is illustrated by the prolongation of 
median graft survival by 63 days with the addition of B cell depleting (anti-CD20) 
therapy in baboons transplanted with hearts from genetically modified pigs [5]. Further 
reducing the immunogenicity of porcine grafts or selectively inhibiting xenotransplant 
reactive antibodies, also known as xenoantibodies, should prolong xenograft survival 
while preserving remaining humoral immune surveillance. Unfortunately, the identity of 
the antigen(s) relevant to rejection of α-1,3-galactosyltransferase knockout (GTKO) 
porcine organs is still an issue of debate [6-8]. 
Clotting factor VIII (FVIII) is a feasible non-Gal-α-1,3-Gal (non-Gal) antigen 
given the recent discovery that endothelial cells synthesize and release FVIII not only in 
hepatic but also in pulmonary, cardiac, intestinal, and dermal microvascular beds [9, 10]. 
Generation of FVIII inhibitors has long been known to be a common side effect for 
patients with hemophilia A receiving FVIII replacement therapy [11] and has even, on 
occasion, been traced to the mutation of a single amino acid of FVIII [12, 13]. There is 
only 76–90% amino acid homology between porcine and human FVIII for those domains 
commonly inhibited [14]. The development of inhibitory anti-FVIII antibodies in a 
xenotransplantation setting is therefore plausible. 
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Our laboratory has identified and characterized the immunoglobulin germline 
genes that encode anti-GTKO xenoantibodies in multiple settings [15, 16]. The induced 
immunoglobulin heavy chain variable (IGHV) genes, VH3-21 and VH3-66, are 92% 
similar and were in germline formation. Antibodies utilizing both these IGHV genes in 
germline configuration have been identified to inhibit clotting factor VIII (FVIII) in 
humans [17]. In this report, we use a two-step chromogenic assay to identify 
xenoantibody FVIII inhibitors developed in response to GTKO/hCD55/hCD59/hHT 
transgenic porcine neonatal islet cell cluster (NICC) transplantation in immune 
suppressed baboons as well as in non-immunosuppressed rhesus monkeys immunized 
with GTKO endothelial cells. Furthermore, we use a combination of homology modeling, 
in silico epitope prediction, competitive ELISA, and in silico polyalanine scanning to 
explore FVIII-xenoantibody interactions. The goal of our study was to characterize 
xenoantibody structure and xenoantibody–antigen interactions that may participate in 
antibody-mediated injury after xenotransplantation of genetically modified porcine 
organs, so that this information can be used to rationally design selective 
immunosuppressive interventions directed at mitigating humoral rejection. 
 
Materials and Methods 
Construction of an anti-non-Gal single-chain xenoantibody 
Representative cloned IgM cDNA sequences, previously isolated from baboons 
demonstrating an active xenoantibody response at day 28 after transplantation with 
GTKO/hCD55/hCD59/hHT porcine NICC xenografts [16], most closely related to the 
human heavy and light chain variable genes, IGHV3-66 and IGKV1D-12, were inserted 
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into a pHEN2 phagemid [Center for Protein Engineering, Medical Research Council 
Center (MRC) Cambridge, UK] [18]. These baboons had developed a xenoantibody 
response despite treatment with a typical immunosuppressive protocol; including a 
combination of induction with ATG and ongoing treatment with mycophenolate mofetil 
and tacrolimus. This single-chain variable fragment (scFv) construct was named 
H66K12. The primers used to clone the IGHV gene were LD3 and VH3BackSFI for the 
first reaction and JH4XHOI and VH3BackSFI for the second reaction. The light chain 
primers were ApaL1.K1D12 and IGJK12NotI. All reactions included 30 cycles; each 
cycle was 94 °C for 30 s, 51 °C for 30 s, and 72 °C for 1 min. The construct was inserted 
in frame as determined by sequencing (Beckman Research Institute at the City of Hope, 
Duarte, CA, USA) using pHEN-SEQ and For_LinkSeq primers. Primer sequences were 
as follows: LD3 5′ TCT GGG GGA GGC TTG GTC 3′; VH3BackSFI 5′ GTC CTC GCA 
ACT GCG GCC CAG CCG GCC ATG GCC CAG GTG CAG CTG GTT GAG TCT 
GGT CG 3′; JH4XHOI 5′ TCG ACC TCG AGC TGA GGA GAC GGT GAC CAG GAC 
TCC CTG GCC CCA GTA GTC CAC CAC TAT AGT AAA AAC ACC CCC TCT 
CGC 3′; ApaL1.K1D12 5′ GTC CTC GCA ACT GCG TGC ACA GGA CAT CCA GAT 
GAC CCA GTC TCC ATC TTC CGT GTC TGC ATC TGT AGG AGA CAA AGT C 
3′; IGJK12NotI 5′ TCG ACG CGG CCG CTT TGA TCT CCA CTT TGG TCC CCT 
GGC CAA AAC TGT ACG GGT AAC TAC TAC CCT GTC GAC AGT AAT AA 3′; 
pHEN-SEQ 5′ CTA TGC GGC CCC ATT CA 3′; FOR_LinkSeq 5′ GCC TTT TCT GTA 
TGA GG 3′. 
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Expression and Purification of Single-Chain Antibody 
Chemically competent Escherichia coli strain HB2151 were transfected with the 
single-chain pHEN2 DNA construct. A 1 : 100 dilution of a bacterial overnight growth 
was used to seed 2xTY media (1% glucose and 1% ampicillin). Bacteria were grown, 
shaking, at 37 °C and 225 rpm until an optical density of 0.8–0.9 at 600 nM. Isopropyl β-
D-1-thiogalactopyranoside was added to a final concentration of 1 mM. After 20–24 h 
shaking at 225 rpm and 30 °C, bacteria were cleared by centrifugation at 1800 g at 4 °C. 
Protein in the bacterial supernatant was concentrated by ammonium sulfate 
precipitation at 80% saturation (4 °C). Precipitated protein was pelleted by centrifugation 
for 15 min at 10 000 g and 4 °C and resuspended to 1/50 initial volume in cold 
phosphate-buffered saline (PBS; pH 7.4). Concentrated protein was dialyzed at 4 °C to 
remove remaining ammonium sulfate. Protein was purified using Ni-NTA agarose resin 
according to manufacturer's instructions, with the exception of using 10 mm imidazole 
wash buffer (Qiagen, Carlsbad, CA, USA). Flow through, washes, and elutions were 
saved for analysis by sodium dodecyl sulfate polyacrylamide gel electrophoresis and 
visualized. The band at 28 KDa was quantified using Imperial Protein Stain (Thermo 
Scientific, Rockford, IL, USA) and carbonic anhydrase (Sigma, St. Louis, MO, USA) 
standards. Total protein in Ni-NTA purified scFv preparations was determined by micro 
BCA assay (Thermo Scientific). 
 
Animals 
Four juvenile rhesus macaques (Macaca mulatta) from the California National 
Primate Research Center, University of California, Davis, CA, USA, were housed in 
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accordance with The American Association for Accreditation of Laboratory Animal Care 
standards. All procedures were in accordance with the requirements of the Animal 
Welfare Act, and protocols were approved prior to implementation by the University of 
California, Davis Institutional Animal Care and Use Committee. 
 
Induction of Anti-Non-Gal Xenoantibodies After Immunization with Porcine GTKO 
Endothelial Cells 
The porcine GTKO endothelial cells (PEGKO42) were kindly provided by Dr. 
David Sachs at Massachusetts General Hospital. Four (2.1–2.4 kg) age-matched (~9 
months of age) rhesus monkeys were selected for low levels of preexisting anti-non-Gal 
xenoantibodies by ELISA using PEGKO42 as a target. Animals were immunized with 60 
× 106 GTKO endothelial cells by intravenous injection (peripheral vessel). These animals 
were not provided any immunosuppression. Serum samples were collected at day 0 and at 
day 7 post-immunization. 
 
Flow Cytometry 
The presence of anti-non-Gal reactive IgM antibodies in sera was confirmed by 
comparison of day 0 and day 7 IgM reactivity to GTKO endothelial cells. Heat-
inactivated serum samples were diluted 1/40 in sterile PBS and incubated with GTKO 
endothelial cells at room temperature (RT) for 60 min. Cells were washed with cold PBS 
and incubated with FITC-conjugated goat (Fab') anti-human IgM (1/50; Jackson 
Immunoresearch, West Grove, PA, USA). Cells were then washed, resuspended in cold 
PBS, and analyzed using a MACSQuant flow cytometer (Becton Dickinson, San Diego, 
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CA, USA) and FlowJo software (Tree stars, Ashland, OR, USA). Incubation with the 
secondary antibody alone was used to measure background. 
 
Detection of FVIII Inhibitors 
Inhibition of FVIII cofactor activity by xenoantibodies was determined using a 
Technochrom two-stage chromogenic assay for FVIII activity (Diapharma Group, Inc., 
West Chester, OH, USA). In this assay, the amount of FXa generated from FX is 
dependent on the FVIII cofactor activity of the sample of interest. Thus, FVIII activity is 
actually calculated from the absorbance of a chromophore produced by cleavage of a 
chromogen by FXa. Advate, recombinant human, von Willebrand factor (vWF) free, 
FVIII (Baxter Healthcare Corporation, Westlake Village, CA, USA) was used in place of 
plasma-derived FVIII. FVIII was mixed with recombinant antibody/control, or serum as 
indicated (in the results) in the provided FVIII dilution buffer. Prepared solutions were 
treated as plasma samples and the remainder of the assay was performed according to the 
manufacturer's instructions using a microtiter plate scheme and the endpoint 
determination method. As indicated, readings of blank wells were used as no measurable 
FVIII activity. All experiments utilized a minimum of two technical replicates. 
 
Computational Modeling 
All in silico work was performed using the Discovery Studio 3.5 suite (Accelrys, 
San Diego, CA, USA) optimized for structural analysis of protein. All crystal structures 
were extracted from the Protein Data Base (RCSB.org) and are listed with their PDB ID 
number. 
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Homology Modeling 
Homology modeling makes use of amino acid sequence similarity to deposited 
crystal structures to generate a three-dimensional protein model which serves as the basis 
for further refinements. Representative amino acid sequences were derived from cloned 
heavy and light chain cDNA sequences of IgM xenoantibodies induced in baboons at 28 
days after transplantation of GTKO/hCD55/hCD59/hHT transgenic porcine NICC [16]. 
The variable fragment (Fv) model of H66K12 was prepared by homology modeling using 
a modeller algorithm optimized for antibody modeling. The antibody framework and 
complementarity determining regions (CDRs) were modeled independently. Framework 
modeling utilized one template so as to optimize the relative positions of each chain. A 
combination of three crystal structures was used to model each separate complementarity 
determining region. Structural refinement of the heavy chain CDR3 was performed using 
a loop refinement protocol, and the lowest energy model from the best scoring cluster 
was chosen for refinement using an implicit solvent-based molecular dynamics 
simulation in CHARM. 
 
In silico Epitope Prediction 
A computer-based protocol for predicting the epitope bound by anti-FVIII 
antibody was first validated by accurately predicting the inhibitory FVIII epitope of 
Bo2C11 (PDB ID 1iqd) using the crystal structure of human FVIII (PDB ID 3CDZ). 
Epitope prediction utilized the shape-based ZDOCK fast Fourier docking protocol. 
ZRANK was used to evaluate docking results. The top-ranked binding orientations 
(poses) from the twenty largest pose clusters were further refined using the RDOCK 
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algorithm which incorporates electrostatic interactions. The average RMSD for the top 
twenty poses was calculated based on the α-carbon distances. 
 
Competition ELISA 
The protocol for a FVIII competition ELISA was adapted from Healey et al. [19]. 
Nunc Maxisorp 96-well plates (Thermo Scientific) were coated with either Ni-NTA 
purified recombinant single-chain xenoantibody, H66K12, or protein purified from E. 
coli transfected with an empty vector matched by total protein (132 μg/ml); 50 μg/ml of 
recombinant scFv, H66K12, was used to coat each experimental well. Wells were coated 
overnight at 4 °C. FVIII was diluted to 0.1 μg/ml in Hepes-buffered saline (pH 7.4) with 
2 mm CaCl2, 0.05% Tween 20, and 2% BSA. The coated plate was washed and 
incubated with diluted FVIII for 60 min at RT. Plates were washed and incubated for an 
hour at RT with 3 μg/ml of either GMA8010 or GMA8011 (Green Mountain Antibodies, 
Burlington, VA, USA). After washing, plates were incubated with horseradish 
peroxidase-conjugated anti-mouse IgG (1/1000; KPL, Gaithersburg, MD, USA) for an 
hour at RT. After a final wash, ABST substrate (KPL) was added and allowed to develop 
for 15 min before reading. All experiments utilized a minimum of three technical 
replicates. 
 
In Silico Polyalanine Scanning 
The most energetically favorable Fv-FVIII complex generated during epitope 
prediction was used to further assess the contribution of individual amino acid residues to 
binding. The “calculate mutation energy” protocol in Discovery Studio was used to 
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mutate individual residues of either FVIII, or the bound Fv, to alanine, and to determine 
the relative contribution of each residue to the energetics of Fv-FVIII interaction. 
Mutations were categorized as stabilizing or destabilizing based on the predicted change 
in affinity. 
 
Statistics 
All statistical analyses were performed using Excel and data represented as mean 
± standard error of the mean. Statistical significance (P < 0.05) compared with an 
untreated control was established using either a Student's t-test or ANOVA. 
 
Results 
The Recombinant Xenoantibody, H66K12, Inhibits FVIII Activity in Vitro 
Our initial investigation utilized recombinant FVIII and a recombinant 
monoclonal scFv xenoantibody, H66K12, because of the ease with which they could be 
experimentally manipulated. H66K12 was constructed from representative cloned cDNA 
IgM sequences derived from baboons demonstrating an active xenoantibody response at 
day 28 after transplantation with 10,000 IEQ/Kg GTKO/hCD55/hCD59/hHT transgenic 
porcine NICC (Fig. 1A,B). These baboons had developed a xenoantibody response 
despite treatment with a typical immunosuppressive protocol, including a combination of 
induction with ATG and ongoing treatment with mycophenolate mofetil and tacrolimus. 
FVIII was diluted to 150 IU/dl, 100 IU/dl, or 50 IU/dl with FVIII dilution buffer alone or 
in combination with either H66K12 or a control matched by total protein (50 μg/ml). The 
final concentration of 28 KDa xenoantibody was 7.75 μg/ml (275 nM). While this 
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antibody concentration is well below the normal physiologic concentration of total 
antibody (630–1830 nM IgM + IgG), it is well above the physiologic concentration of 
xenoantibody (0.3–1.2 nM IgM + IgG) [20]. However, this experiment was meant to 
indicate, convincingly, that recombinant xenoantibody is capable of effectively inhibiting 
the cofactor activity of FVIII. Compared with control, H66K12 significantly inhibited 
FVIII cofactor activity at every concentration of FVIII (P < 0.001; Fig. 1C). 
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B 
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Figure 1. Recombinant single chain xenoantibody (H66K12) inhibits FVIII cofactor 
activity. A recombinant single chain xenoantibody, H66K12, was constructed from 
representative cloned cDNA IgM sequences derived from baboons demonstrating an 
active xenoantibody response at day 28 after transplantation with 
GTKO/hCD55/hCD59/hHT transgenic porcine NICC. (A) Schematic of pHEN 
phagemid containing the H66K12 single chain antibody encoded by the IGHV3-66 and 
IGKV1-12 germline genes. (B) Amino acid translation of the recombinant anti-nonGal 
single chain antibody H66K12. Complementarity determining regions are labeled 
according to the Kabat annotation system. (C) Recombinant FVIII was diluted to the 
final concentration indicated. FVIII alone or FVIII with 50 ug/ml of protein (control) 
was used for comparison. H66K12 was added to a final concentration of 7.75 ug/ml 
(275 nM) and matched to the control by total protein. A two-stage chromogenic assay 
was used to determine resulting FVIII cofactor activity. H66K12 significantly inhibited 
FVIII cofactor activity. (# indicates p < 0.001). Ampicillin resistance gene (amp), origin 
of replication (ori), Ribosomal binding site (RBS), Heavy chain (IGHV), Light chain 
(IGKV), FWR (framework region), CDR (complementarity determining region), 
Recombinant xenoantibody (H66K12) - rXAb. 
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Serum Derived Xenoantibody Inhibits FVIII Activity in Vitro 
We have previously used intravenous injection of GTKO porcine endothelial cells 
to initiate a humoral immune response in rhesus monkeys to study the DNA and amino 
acid sequences of the induced xenoantibodies [15]. These animals were not provided any 
form of immunosuppression. In the current study, we used samples from these 
experiments to assay for an escalation of xenoantibodies which inhibit FVIII cofactor 
activity. Flow cytometry was used to measure serum IgM binding to GTKO porcine 
endothelial cells. At day 7, binding was 71.6% compared with 0.66% at day 0, 
confirming the initiation of an anti-non-Gal immune response (Fig. 2A). 
Clotting factor VIII was diluted with FVIII dilution buffer alone or in 
combination with either human or monkey serum (1/20 final serum dilution). FVIII 
concentrations were maintained within what is considered the normal human physiologic 
range. Inhibition of FVIII activity by pre-transplant serum may reflect structural 
differences between human and rhesus monkey FVIII. Data collected using serum from 
four animals demonstrated significantly increased inhibition of FVIII cofactor activity 
after immunization at FVIII concentrations 150 IU/dl (P < 0.05), 100 IU/dl (P < 0.05), 
and 50 IU/dl (P < 0.001; Fig. 2B). At 150 IU/dl and 100 IU/dl FVIII concentration, 
activity was reduced by 60% when comparing inhibition by pre- and post-transplant 
serum. This is consistent with an increase in inhibitor titer by approximately 16 Bethesda 
units (Bu); where an increase over 5 Bu in humans can indicate pathology. 
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Figure 2. Serum antibody from rhesus monkeys immunized with GTKO porcine 
endothelial cells inhibits FVIII cofactor activity. (A) Rhesus monkeys were immunized 
with GTKO porcine endothelial cells to stimulate an anti-nonGal humoral immune 
response. Flow cytometry was used to measure serum IgM binding to GTKO endothelial 
cells. The dashed and solid curves with no shading represent binding at days 0 and 7, 
respectively. The shaded curve represents background determined by incubation with 
secondary antibody alone. (B) A two-stage chromogenic assay was used to measure 
FVIII activity. Recombinant FVIII was diluted to the final concentrations indicated. 
FVIII alone or FVIII with human serum diluted 1/20 was used as controls. The extent 
to which FVIII cofactor activity was inhibited by xenoantibody at day 0 and 7 was 
compared in four animals. There was a significant decrease in FVIII cofactor activity 
with the addition of post-immunization serum at day 7, compared to day 0, at every 
FVIII dilution. (* indicates p < 0.05; # indicates p < 0.001) Human serum – HS; Monkey 
serum (MS). 
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Computer Modeling Predicts Induced Xenoantibody Binds the FVIII C1 Domain 
Computer modeling was used to address the question of which FVIII domain was 
bound by H66K12. Using homology, we generated an Fv structural model. All templates 
used are listed in Table 1. Figure 3 depicts a Ramachandran plot demonstrating the 
favorable energetics of our final model. A computer-based protocol for predicting the 
relevant epitope was first validated by accurately predicting the inhibitory FVIII epitope 
of Bo2C11 (1iqd) using the crystal structure of human FVIII (3CDZ). This protocol was 
able to accurately predict 14 of 18 FVIII residues which come within 5 Å of Bo2C11 
(Fig. 4). The A1 domain was excluded because those FVIII inhibitors characterized to 
date are known to predominantly bind the A2, A3, C1, and C2 domains, but not the A1 
domain [19, 21]. The ZDOCK docking algorithm was used to search for initial 
complementarity between FVIII and H66K12 based on the shape. The top-ranked binding 
orientations (poses) from the twenty largest clusters of poses were further refined using 
the RDOCK algorithm which incorporates electrostatic interactions. All of the top twenty 
final binding orientations were nearly identical (average RMSD 9.99) and bound the C1 
domain. The top scoring pose bound to FVIII is illustrated in Fig. 5. 
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Table 1. Templates used for homology modeling 
Region PDB Similarity Identity Resolution Organism 
HFR 3bn9 98.9% 90.1% 2.173 Homo sapiens 
LFR 3bn9 94.5% 94.4% 2.173 Homo sapiens 
HCDR1 1fh5 100.0% 100.0% 2.9 Homo sapiens 
 2h1p 100.0% 87.5% 2.4 Mus musculus 
 2v17 87.5% 75.0% 1.65 Mus musculus 
HCDR2 3ls5 85.7% 85.7% 1.9 Mus musculus 
 3cfb 85.7% 85.7% 1.6 Mus musculus 
 3utz 85.7% 85.7% 2.18 Escherichia coli 
HCDR3 3l95 66.7% 58.3% 2.19 Escherichia coli 
 3r1g 58.3% 50.0% 2.8 Homo sapiens 
 3eyo 75.0% 41.7% 2.5 Homo sapiens 
LCDR1 3hmw 100.0% 100.0% 3 Homo sapiens 
 3bn9 100.0% 83.3% 2.173 Homo sapiens 
 2x7l 83.3% 83.3% 3.17 Escherichia coli 
LCDR2 1dfb 100.0% 100.0% 2.7 Homo sapiens 
 2cmr 100.0% 100.0% 2 Homo sapiens 
 3ncj 66.7% 66.7% 1.6 Homo sapiens 
LCDR3 1yjd 88.9% 55.6% 2.7 Mus musculus 
 3ncj 77.8% 44.4% 1.6 Homo sapiens 
 1iai 77.8% 55.6% 2.9 Mus musculus 
H- heavy; L- light; FR- framework region;  
CDR- complementarity determining region 
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Figure 3. Ramachandran plot of the refined model of H66K12. Ramachandran plot of 
the refined model of the xenoantibody derived from representative cloned cDNA IgM 
sequences from baboons demonstrating an active xenoantibody response at day 28 after 
transplantation with GalKO/hCD55/hCD59/hHT transgenic porcine islets. Triangles 
represent glycine residues, squares represent proline residues, while circles represent 
all other amino acids. 
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          2195           2213 
           |              | 
CrystalC2 YFTNMFATWSP    HLQGRSNAWRPQVNNP 
ModeledC2 YFTNMFATWSP    HLQGRSNAWRPQVNNP 
 
 
          2244                2288      2314 
           |                   |         | 
CrystalC2 TTQGVKSLLTSMYV      DSFTP     VHQIALRME 
ModeledC2 TTQGVKSLLTSMYV    DSFTP    VHQIALRME 
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Figure 4. Molecular modeling accurately predicts 14/18 FVIII C2 domain amino acid 
residues that make contact with Bo2C11. A computer-based protocol for predicting the 
epitope bound by a particular anti-FVIII antibody was first validated by accurately 
predicting the domain bound by Bo2C11. Of 18 FVIII residues which come within 5 Å 
of Bo2C11 in the deposited crystal structure (PDB ID 1iqd), 14 residues are accurately 
predicted using molecular modeling. Highlighted residues come within 5 Å of Bo2C11; 
Modeled C2 indicates residues predicted using computer modeling. 
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 Figure 5. In silico protein-docking algorithms predict xenoantibody binds the FVIII C1 
domain. Representative cloned IgM cDNA sequences from baboons actively responding 
to transplantation of GTKO/hCD55/hCD59/hHT porcine NICC were used to model the 
variable fragment of H66K12 by homology. Docking this antibody model with the 
crystal structure of human FVIII (PDB ID 3CDZ) using shape complementarity, then 
refinement with electrostatics, predicted binding to the C1 domain of FVIII. FVIII is 
depicted as a space filling model and domains are labeled. The best binding motif of 
H66K12 is depicted as a ribbon model.  
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Competition ELISA Confirms Induced Xenoantibody Binds the FVIII C1 Domain 
We used a competition ELISA to determine the accuracy of the in silico epitope 
prediction. We reasoned that if we captured FVIII using the recombinant xenoantibody 
H66K12, we should be able to detect it with an antibody which binds elsewhere on the 
light chain (GMA-8010), but not an inhibitory antibody which binds the C1 domain 
(GMA-8011). This is because H66K12 would mask the epitope recognized by GMA-
8011, but not by GMA-8010. Our results illustrated in Fig. 6 demonstrate that the in 
silico prediction was correct. FVIII captured by H66K12 is detectable with GMA-8011, 
but not by GMA-8010. Furthermore, this effect is not present if a control protein 
suspension generated from an empty vector is used to “capture” FVIII. 
 
In Silico Binding Site Mutation Analysis 
To determine which residues of both H66K12 and FVIII contribute the most to 
binding, polyalanine scanning was performed in silico. Table 2 provides a list of residues 
which, when mutated, stabilize or destabilize the protein–protein interaction. Those 
residues in the xenoantibody are of particular interest. The heavy chain amino acid 
sequence induced in baboons in response to transplantation of 
GTKO/hCD55/hCD59/hHT transgenic porcine NICC and in rhesus monkeys immunized 
with GTKO porcine endothelial cells are 92% similar [16]. Furthermore, the light chain 
germline variable genes utilized in response to wild-type porcine organs and 
GTKO/hCD55/hCD59/hHT are the same [16]. Here, we report that the most important 
amino acids of both the heavy and light chains are conserved in each case; Tyr33 in the 
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heavy chain and Trp32 in the light chain. Thus, rational design of xenoantibody inhibitors 
would target these residues. 
Alignment of human and porcine amino acid sequences of FVIII (Fig. 7A) 
demonstrates that most amino acid residues, which are predicted, to contribute to this 
interaction are conserved. Interestingly, Phe2068, present only in human FVIII, is 
predicted to be the most important individual amino acid. Those FVIII residues which are 
predicted to interact favorably with xenoantibody (the most destabilizing mutations) are 
illustrated in Fig. 7B. 
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Table 2. In silico polyalanine scanning to predict amino acid contributions 
to FVIII-Fv interaction 
FVIII - C1 Kcal/mol* Fv - LC Kcal/mol* Fv - HC Kcal/mol* 
Arg2150 +1.72 Lys50 -2.45 Try100c +1.29 
Met2104 +1.82 Ser30 -1.92 Tyr33 +2.58 
Trp2046 +2.07 Ser31 -1.84 
Trp2070 +2.42 Leu33 -1.52 
Phe2068 +4.43 Ser53 -1.26 
Ser52 -1.22 
Gly91 +1.20 
Try95e +1.74 
Trp32 +5.18 
Fv- variable fragment; LC- light chain; HC- heavy chain; *predicted 
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Figure 6. Competition ELISA confirms xenoantibody binds to the FVIII C1 domain. 
Protein generated from a control construct (I) or H66K12 (50 ug/ml) (II) was used to 
capture FVIII. Capture solutions were matched for total protein content of 132 ug/ml. 
FVIII was detected with either a FVIII C1 domain-binding inhibitory antibody (GMA-
8011) or an antibody which binds elsewhere on the FVIII light chain (GMA-8010). 
The results are illustrated both as a picture (A) and as a graph (B). # indicates p < 0.01; 
Light chain – LC; A – control capture solution; B – Capture with recombinant 
xenoantibody. 
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           2010      2030      2040      2050      2060      2070 
            |         |         |         |         |         | 
HSFVIII-C1  KCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSW 
SSFVIII-C1  E--AP------R----------------------------------D-H-- 
 
                    2080      2090      2100      2110      2120 
                     |         |         |         |         | 
HSFVIII-C1  IKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTG 
SSFVIII-C1  --------------M------------------------RN--S------- 
 
                   2130      2140      2150      2160      2170 
                    |         |         |         |         | 
HSFVIII-C1  TLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLN 
SSFVIII-C1  ----------A------------V--------------------------- 
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  Figure 7. Four of five FVIII residues important for xenoantibody binding are 
homologous with porcine FVIII. (A) Alignment of human and porcine FVIII amino 
acid sequences with residues thought to contribute to binding recombinant 
xenoantibody highlighted and in bold. (B) The structure of FVIII C1 domain (blue) 
with predicted binding sites labeled and highlighted in yellow. (Sus scrofa accession 
NM_214167.1; Homo sapiens extracted from crystal structure PDB ID 3cdz) 
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Discussion 
The impact of the immune system on coagulation dysregulation during 
xenotransplantation and xenograft rejection remains to be fully elucidated. We report the 
generation of antibodies, which inhibit human FVIII cofactor activity after 
transplantation of immunosuppressed baboons with GTKO/hCD55/hCD59/hHT 
transgenic porcine NICC and immunization of rhesus monkeys with GTKO porcine 
endothelial cells. While a prothrombotic response, such as consumptive coagulopathy, is 
predominant during acute xenograft rejection within hours to days, development of FVIII 
inhibitors is likely to impact long-term xenotransplantation. The recombinant 
xenoantibody, H66K12, generated from post-NICC xenotransplantation IgM 
xenoantibody sequences, binds to the C1 domain of FVIII. Targeting the xenoantibody 
pocket, which makes contact with FVIII, may be a promising strategy for selectively 
countering these inhibitors. However, it is unknown whether other FVIII domains are 
targeted as well. Nevertheless, FVIII inhibitors developed in response to transplantation 
with GTKO cells represent a novel pathologic effect on recipient physiology. 
Clotting factor VIII is synthesized as a 330-KDa precursor protein with an A1-α1-
A2-α2-B-α3-A3-C1-C2 domain structure [21]. Inhibitory antibodies against FVIII are 
known to bind several domains including the A2, A3, C1, and C2 domains in addition to 
the acidic α1 region between the A1 and A2 domains. In humans, inhibitors against the 
C2 domain have been primarily determined to belong to the VH1 family [22]. However, 
these antibodies are often extensively modified by hypersomatic mutation and have 
atypically long CDR3 loops (20–23 amino acids). In contrast, inhibitors that bind the A2 
and A3 domains display more variation. Anti-A2 antibodies have been reported from 
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VH1, VH3, VH5, and VH6 families while anti-A3 antibodies are derived from VH1 and 
VH3 families [23, 24]. By comparison, the VH genes that generate inhibitors of the C1 
domain have not been previously characterized. However, analysis of the deposited 
sequence of KM33, which binds the C1 residues Lys2092 and Phe2093 [25], 
demonstrates 87.8% identity to IgHV3-30 providing an additional C1 inhibitor which 
utilizes a member of the VH3 family. The light chain antibodies that contribute to FVIII 
inhibitors have not been so extensively characterized. However, similar to H66K12, 
KM33 also utilizes a VK1 family member and demonstrates 86.2% identity to IgKV1-6. 
Clotting factor VIII inhibitors that bind the C1 domain can affect interactions with 
either vWF [26] or phosphatidylserine [27, 28]. Given that the FVIII preparation utilized 
in this study is vWF free [29], inhibition of membrane binding is the more relevant 
mechanism in vitro for the induced xenoantibody. However, human antibodies that bind 
to FVIII Arg2150 inhibit FVIII binding to vWF. As H66K12 is predicted to interact with 
Arg2150, it likely inhibits this interaction and would reduce FVIII half-life in vivo. The 
C1 domain is known to contribute to membrane binding [27] via Lys2092 and Phe2093 
[28]; however, these residues are relatively distant from the predicted binding site. Recent 
experiments using fluorescence energy resonance transfer have determined the angle at 
which FVIII interacts with phospholipid membranes [30]. Given the distance from 
Lys2092 and Phe2093, H66K12 might bind residues which interact directly with 
phospholipid or act in a steric fashion. At least one amino acid predicted to interact with 
H66K12, Trp2046, is only one residue away from a large, positively charged region of 
the FVIII C1 domain predicted to interact with negatively charged phosphatidylserine. 
Binding of FVIII to vWF significantly increases its half-life while interaction with 
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phospholipid is essential for cofactor function [21]. In vivo, it is likely that both these 
mechanisms can contribute to diminished FVIII function. However, the specific 
mechanism(s) by which induced xenoantibody inhibits FVIII function will require further 
investigation. 
In this study, we used human FVIII as a source of primate FVIII assuming the 
sequences are largely similar; the sequences of rhesus monkey and baboon FVIII have 
not been characterized. In the context of xenotransplantation, it is reasonable to speculate 
that FVIII inhibitors are initiated by porcine FVIII. Humans can “break” tolerance when 
they develop acquired hemophilia A [31] or when provided an exogenous source of FVIII 
via FVIII replacement therapy [11-13]. Thus, xenotransplantation may trigger a lapse in 
tolerance to the FVIII autoantigen by providing a source of exogenous FVIII. Four of five 
FVIII residues predicted to interact most favorably with H66K12 are conserved between 
pigs and humans. However, a single amino acid difference can contribute to the 
development of inhibitors [12, 13], and humanization of porcine FVIII C1 may preempt 
formation of antibodies directed at this domain. Of note, there is evidence that anti-CD20 
therapy can mitigate the acquisition of FVIII inhibitors in both acquired and inherited 
hemophilia A [31]. However, in the context of xenotransplantation, anti-CD20 therapy 
represents a significant addition to an already cumbersome immunosuppressive burden. 
The prevalence of induced anti-FVIII antibodies in other xenotransplantation 
settings is currently unknown. However, FVIII has recently been demonstrated to be 
expressed in the microvasculature of multiple sites including the liver but also lung, 
heart, intestine, and dermis [9, 10]. Each model of xenotransplantation has variations in 
pathology and time to rejection with typical immunosuppressive regimens [1, 32-36]. 
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Current reports in xenotransplantation provide clues as to where antibodies against FVIII 
might contribute to pathology. 
The level of FVIII in the porcine serum is significantly higher than that of 
baboons [37]. When the anti-fibrinolytic agent Amicar is provided before xenograft 
reperfusion to prevent thrombocytopenia, it does not overcome spontaneous bleeding. 
Initial investigations provide normal coagulation parameters for genetically modified pigs 
or typical primate species utilized in xenotransplantation [38]. However, the “normal” 
coagulation parameters expected after xenotransplantation are currently under 
investigation [4, 37]. Our results indicate pre-transplant serum antibody can also affect 
FVIII activity and further obscure the practicality of traditional assays using human 
clotting factors. To thoroughly dissect coagulation dysregulation in xenotransplantation, 
partial thromboplastin time and international normalized ratio assessment should be used 
in combination with ELISA for clotting factors and chromogenic assays to assess specific 
factor activity levels and the impact of acquired inhibitors. 
Mohiuddin et al. [5] reported extended survival times during cardiac 
xenotransplantation with the addition of B cell depleting therapy. However, the presence 
of remaining IgM, but primarily IgG, deposition at explant provides evidence of 
remaining humoral impact. Interestingly, three of those animals with extended survival 
times were noted to have died from abdominal bleeding due to unknown causes. 
Our co-authors have recently performed thromboelastographic analysis of 
cynomolgus monkeys after transplantation of porcine GTKO kidneys with various 
transgenes. They demonstrate progressive prolongation of clotting time via the intrinsic 
clotting cascade which could be accounted for by either severe deficiencies of the 
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intrinsic clotting cascade or alternatively, FVIII inhibitors [4]. However, the expression 
of FVIII in the renal microvasculature has never been investigated. 
The specific impact of anti-FVIII antibodies on delayed humoral xenograft 
rejection in each model of xenotransplantation will require further investigation. Whether 
FVIII inhibitors precipitate graft rejection or exacerbate more prevalent xenograft 
pathology will need to be determined. Those grafts that survive long enough to be subject 
to an adaptive humoral response are more likely to generate FVIII inhibitors. Future 
experiments should incorporate monitoring of anti-FVIII antibodies. The development of 
FVIII inhibitors in xenotransplantation is, however, an illustration of the functional 
impact the humoral immune response can illicit. The expansion of xenoantibodies, which 
are capable of binding both human and non-human primate proteins, is not likely to be an 
isolated incident, and xenoantibodies may have other functional effects which alter the 
physiology of both host and graft. 
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Abstract 
Background: Survival of vascularized xenografts is dependent on preemptive 
inhibition of the xenoantibody response against galactosyltransferase knockout (GTKO) 
porcine antigens. Our analysis in multiple GTKO pig-to-primate models of 
xenotransplantation has demonstrated that the anti-non-gal-α-1,3-gal (anti-non-Gal) 
xenoantibody response displays limited structural diversity. This allowed our group to 
identify an experimental compound which selectively inhibited induced anti-non-Gal 
IgM xenoantibodies. However, because this compound had an unknown safety profile we 
extended this line of research to include screening small molecules with known safety 
profiles allowing rapid advancement to large animal models. 
Methods: The NIH clinical collections of small molecules were screened by 
ELISA for their ability to inhibit xenoantibody binding to GTKO pig endothelial cells. 
Serum collected from non-immunosuppressed rhesus monkeys at day 14 after injection 
with GTKO pig endothelial cells was utilized as a source of elicited xenoantibody for 
initial screening. Virtual small molecule screening based on xenoantibody structure was 
used to assess the likelihood that the identified small molecules bound xenoantibody 
directly. As a proxy for selectivity, ELISAs against tetanus toxoid and the natural 
antigens laminin, thyroglobulin, and single stranded DNA (ssDNA) were utilized to 
assess the ability of the identified reagents to inhibit additional antibody responses. The 
identified inhibitory small molecules were further tested for their ability to inhibit 
xenoantibody elicited in multiple settings including: rhesus monkeys pre-treated with an 
anti-non-Gal selective anti-idiotypic antibody, non-immunosuppressed rhesus monkeys 
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immunized with wild type fetal pig islet-like cell clusters, and non-immunosuppressed 
baboons transplanted with GTKO multiple transgenic pig kidneys. 
Results: Four clinically relevant small molecules inhibited anti-non-Gal IgM 
binding to GTKO pig endothelial cells in vitro. Three of these drugs displayed a limited 
region of structural similarity suggesting they may inhibit xenoantibody by a similar 
mechanism. One of these, the anti-hypertensive agent clonidine, displayed only minimal 
inhibition of antibodies elicited by vaccination against tetanus toxoid or pre-existing 
natural antibodies against laminin, thyroglobulin, or ssDNA. Furthermore, clonidine 
inhibited elicited anti-non-Gal IgM from all animals that demonstrated a xenoantibody 
response in each experimental setting. 
Conclusions: Clinically relevant small molecule drugs with known safety profiles 
can inhibit xenoantibody elicited against non-Gal antigens in diverse experimental 
xenotransplantation settings. These molecules are ready to be tested in large animal 
models. However, it will first be necessary to optimize the timing and dosing required to 
inhibit xenoantibodies in vivo. 
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Introduction 
Xenotransplantation of genetically modified porcine organs and cells is 
approaching clinical relevance (1). Multiple laboratories have demonstrated xenoislet 
survival of over one year using non-human primate recipients (2-4) and transplantation of 
encapsulated pig pancreatic islets is currently in clinical trials (5). More critically, in the 
extremely onerous heart transplant model, Mohiuddin et al. achieved a median survival 
time of over 200 days with a maximum survival time of approximately 600 days at the 
time of publication [reported in supplementary discussion in print edition], albeit in a 
non-life supporting pig-to-primate model (6). Preemptively inhibiting the xenoantibody 
response against non-α-1,3-gal terminal disaccharide (non-Gal) antigens present on pig 
xenografts is important for long term survival of vascularized xenografts (6-8) and thus 
translation to the clinic. To this end, perioperative B cell depletion with anti-CD20 
dramatically prolongs survival of cardiac xenografts (8). However, in the context of 
transplantation, B cell depletion is known to result in a greater risk of infection and 
infection-related death (9-11). Targeted inhibition of the anti-non-Gal humoral immune 
response both perioperatively, and long-term postoperatively, could enhance xenograft 
survival while preserving the greater portion of B cell-mediated adaptive immunity to 
ward off infection. 
Our group has previously demonstrated that the elicited anti-non-Gal 
xenoantibody response displays limited structural diversity in multiple 
galactosyltransferase knockout (GTKO) pig-to-primate models of xenotransplantation 
(12, 13). This enabled us to identify an anti-non-Gal selective anti-idiotypic single chain 
antibody and an experimental small molecule capable of selectively inhibiting induced 
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anti-non-Gal IgM xenoantibodies (14). Although in vitro this small molecule could 
inhibit the binding of residual IgM xenoantibody, in animals pre-treated with anti-
idiotypic antibody, it had an unknown safety profile. We therefore extended this line of 
research to include screening of the NIH clinical collections, which consist almost 
entirely of small molecules with a history of use in clinical trials. We report here the 
identification of small molecule drugs with known safety profiles which selectively 
inhibit anti-non-Gal xenoantibody, allowing rapid translation to experiments in large 
animal models. 
 
Materials and Methods 
Animals 
Fifteen juvenile and two adult rhesus monkeys (Macaca mulatta) from the 
California National Primate Research Center, University of California, Davis, CA were 
utilized in this study. All procedures met the requirements of the Animal Welfare Act. 
Protocols were approved prior to implementation by the University of California, Davis 
Institutional Animal Care and Use Committee. 
Six baboons (Papio hamadryas) were supplied by the NH&MRC Australian 
National Baboon Colony, Sydney, Australia. All procedures were approved by Local 
Area Health Service Animal Ethics Committees and conducted in compliance with State 
Government legislation and NH&MRC Animal Research Guidelines. 
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Models of Xenotransplantation 
Immunization with GTKO pig aortic endothelial cells 
Fifteen juvenile rhesus monkeys were screened for low levels of non-Gal-reactive 
xenoantibody by ELISA as previously reported (14). Five animals with the lowest levels 
of pre-existing anti-nonGal IgM xenoantibody were selected for further study. Two non-
immunosuppressed animals (NIS.A and NIS.B) were intravenously injected with GTKO 
pig aortic endothelial cells (PAECs) in the absence of immunosuppression. This allowed 
for the induction of an anti-nonGal xenoantibody response without the procedural 
complications of islet or solid organ xenotransplantation. Three additional animals 
(AIA.A-C) were pre-treated with a novel anti-non-Gal selective anti-idiotypic single 
chain antibody (B4N190). This anti-idiotypic antibody was generated in our laboratory 
using a sequence and structure based approach to select a reagent specific for induced 
anti-non-Gal antibody. The anti-idiotypic antibody was administered once per week for 
three weeks before immunization with GTKO PAECs. 
 
Islet Xenotransplantation 
Two non-immunosuppressed adult rhesus monkeys (ISLET.1-2) were immunized 
with wild type fetal porcine islet-like cell clusters in order to elicit a xenoantibody 
response, as previously reported (15). Briefly, fetal porcine islet-like cell clusters (15 x 
106 cells) were prepared by culturing collagenase-digested pancreata from fetuses at 66 
days of gestation (term ~114 days). Cells were cultured for 1-3 weeks before 
intraperitoneal injection on experimental day 0. Serum samples from the current set of 
studies were collected before immunization on day 0 and on day 8 after immunization. 
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Kidney Xenotransplantation 
Genetically modified pigs (Sus scrofa), which were GTKO and co-expressed 
human CD55, CD59, and α 1,2-fucosyltransferase (H-transferase, HT) were generated by 
Cowan et al. (16, 17). Six non-immunosuppressed baboons (KIDNEY.1-6) were 
transplanted with GTKO/hCD55/hCD59/hHT pig kidneys. Additional details regarding 
the conditions of transplant will be published separately by our collaborators. The grafts 
from two animals (KIDNEY.1 and KIDNEY.2) survived over 100 hours. This was a 
sufficient length of time for the anti-non-Gal xenoantibody response to be detectable in 
peripheral blood. Serum samples from the current studies were collected from these two 
animals on day 0 and at the time of rejection.  
 
Small Molecule Library 
The NIH Clinical Collections 1 and 2 composed of 446 and 281 compounds 
respectively consist of drugs selected for their history of use in clinical trials, purity, 
solubility, and availability from commercial sources. The NIH Clinical Collections were 
provided through the National Institutes of Health Molecular Libraries Roadmap 
Initiative. Fifty microliters of each drug was provided in a 96-well plate format diluted to 
10 mM in DMSO. Furthermore, these drugs were dispensed into 96-well plates in an 
anoxic environment and stored at ≤-70°C to ensure minimal degradation during shipping 
and storage before screening. 
 
In Vitro Small Molecule Screening 
The xenoantibody response and inhibition by small molecule drugs was measured 
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by ELISA as previously described (18) but using GTKO/hCD55 PAECs as targets. 
GTKO/hCD55 PAECs (NSRRC:0009) were purchased from the National Swine 
Research and Resource Center (Columbia, MO). Initial screening for drugs with the 
ability to inhibit xenoantibody responses was performed to identify promising candidates. 
These candidates were then tested in triplicate with at least two independent repeated 
experiments. Individual plates of drugs were allowed to thaw at room temperature before 
drugs were diluted to 60 μM in blocking solution for screening. Blocking solution was 
composed of 1x phosphate buffered saline (pH 7.4) with 0.05% tween-20 and 2% bovine 
serum albumin. This was then mixed 1+1 with serum (1:50 in blocking solution) to 
obtain a solution with a final drug concentration of 30 μM and serum 1:100 dilution. This 
solution was allowed to equilibrate at room temperature for 15-30 minutes before 
incubation with GTKO/hCD55 PAECs at room temperature for one hour. Anti-human 
IgM HRP (1:1000) (Jackson Immunoresearch, West Grove, PA) was used as a secondary 
antibody. Each plate of NIH Clinical Collection drugs was re-frozen at ≤-70°C after each 
study and utilized a maximum of five times. After initial screening each drug identified to 
inhibit anti-non-Gal IgM xenoantibody was purchased from a commercial source. 
 
In Silico Small Molecule Screening 
The anti-non-Gal IgM xenoantibody response is known to display a high degree 
of sequence variation in the heavy and light chain third complementarity determining 
regions (CDRs) (12, 13). Thus, inclusion of multiple xenoantibody structural models was 
required to refine our previous virtual screening process and account for this inherent 
structural variation. All three xenoantibody models were encoded by representative 
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xenoantibody sequences, which were highly similar within the CDR1 and CDR2 regions. 
Consistent with our previous analysis, each heavy chain utilized the IGHV3-66 and 
IGHJ4 germline genes. However, the heavy chain CDR3 amino acid translation displayed 
a high degree of variation. All three xenoantibody models utilized in our refined small 
molecule screening protocol were generated using the ROSIE antibody-modeling server 
(19), which has been demonstrated to have comparable accuracy to discovery studio (20) 
which we previously utilized. The combination of autodock vina (21) and PyRx (22) 
were used to perform virtual screening over the entire antigen-binding region of each 
model. The entirety of the NIH clinical collections was screened against each 
xenoantibody model. The results of each independent screen were ranked by predicted 
affinity. Those molecules from the NIH clinical collection which were predicted to be in 
the top 30% using all three xenoantibody structural models, and inhibited xenoantibody 
in vitro, were considered to be the most likely to bind directly to anti-non-Gal 
xenoantibody. 
 
Natural Antibody ELISA 
Natural antibody ELISAs were performed as previously described (14). Briefly, 
single stranded DNA (ssDNA) (Sigma, St. Louis, MO), laminin (Sigma, St. Louis, MO), 
and thyroglobulin (Sigma) were pre-coated on 96 96-well plates at a concentration of 20 
μg/well. Serum (1:100) with, or without drug (30 µM), in blocking solution was 
incubated one hour at room temperature with the antigen of interest. Anti-human IgM 
HRP (1:1000) (Jackson Immunoresearch, West Grove, PA) was used as a secondary 
antibody. After 10 minutes incubation at room temperature with 100 µl of OPD solution 
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(Pierce Biotechnology, Rockford, IL) development was stopped using 50 µl of 2.5 M 
sulfuric acid and read at 490 nm. 
 
Tetanus Toxoid IgG ELISA 
Tetanus toxoid IgG titer ELISA was performed according to the manufacturer’s 
instructions (Genway biotech, San Diego, CA) with one exception. Either a stock small 
molecule suspension or an equal volume of vehicle was added as necessary to the serum 
diluent of the experimental and control conditions respectively. Serum was diluted 1:101 
as per the manufacturer’s instructions while the final concentration of clonidine was 30 
µM. A standard curve calibrated against the World Health Organization reference 
preparation enabled us to quantify anti-tetanus toxoid IgG in international units per 
milliliter (IU/ml). 
 
Statistical Analysis 
All statistical analyses were performed using Excel. Data is represented as mean ± 
standard error of the mean (SEM) of at least three technical replicates. Statistical 
significance (P-value < 0.05) was established using a 2-tailed Student’s t-test or analysis 
of variance as appropriate. 
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Results 
Screening for Clinically Relevant Small Molecule Drugs Capable of Inhibiting Anti-
Non-Gal Xenoantibody 
Serum collected from non-immunosuppressed animals 14 days after injection 
with GTKO PAECs was used as a source of anti-non-Gal IgM xenoantibody for 
screening. Drugs were initially screened for the ability to inhibit induced xenoantibodies 
from one monkey (NIS.A), because this animal had a larger anti-non-Gal xenoantibody 
response allowing more sensitive detection of inhibition. This also minimized the 
quantity of serum required in early stage screening experiments. However, promising 
candidates were retested for the ability to inhibit binding of xenoantibodies elicited in 
both NIS.A and NIS.B. Over the course of screening all 727 molecules, four compounds 
were identified to inhibit 23-64% of IgM xenoantibody elicited in non-
immunosuppressed rhesus monkeys (Fig. 1). Gabexate mesilate, a protease inhibitor 
utilized in treatment of acute pancreatitis (23) was able to inhibit 24-34% of induced IgM 
xenoantibody. Oxiconazole, an azole anti-fungal agent (24) was able to inhibit 31-48% of 
induced IgM xenoantibody. Clonidine, an α2 adrenergic receptor agonist most commonly 
used to treat hypertension (25) was able to inhibit 30-48% of induced IgM xenoantibody. 
Voriconazole, a triazole anti-fungal agent (24) was able to inhibit 39-64% of induced 
IgM xenoantibody.  
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Figure 1. The NIH clinical collections of small molecule drugs were screened by ELISA 
against GTKO/hCD55 pig aortic endothelial cells. Serum collected from two non-
immunosuppressed rhesus monkeys (NIS.A and NIS.B) at day 14 (D14) after 
immunization with GTKO pig endothelial cells was utilized as a source of elicited 
xenoantibody. Gabexate mesilate (GM), oxiconazole (OX), clonidine (Clon), and 
voriconazole (VCZ) were identified to inhibit elicited anti-non-Gal IgM. These drugs 
were able to inhibit 23.5-38.6% of the anti-non-Gal IgM xenoantibody elicited by NIS.A 
and 34.4-64.1% elicited by NIS.B. Values are reported as both the (A) % inhibition ± 
the standard error of the mean (SEM) and (B-D) the optical density (OD) ± SEM. % 
inhibition = 100% x [D14OD – (D14 with drug)OD]/(D14OD – D0OD); * indicates P 
< 0.05 compared to D14 without drug. 
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In Silico Small Molecule Screening Suggests Azole Antifungals Bind Directly to 
Xenoantibody 
All xenoantibody sequences utilized in antibody modeling were representative of 
those elicited in baboons responding to xenotransplantation with 
GTKO/hCD55/hCD59/hHT neonatal islet-like cell clusters (13). We sought to refine our 
previous in silico screening process by more accurately representing the diversity of 
xenoantibody CDR3 regions. The ROSIE antibody-modeling server (19) was utilized to 
generate three xenoantibody models. Variations in xenoantibody CDR3 amino acid 
sequences resulted in notable differences in the predicted structure of the heavy chain 
CDR3 and to a lesser degree the light chain CDR3 (Fig. 2). However, these differences 
had little impact on the structures and relative positioning of the heavy and light chain 
CDR1 and CDR2 loops.  
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Figure 2. Three structural models of xenoantibody encoded by the germline genes 
IGHV3-66 and IGKV1D-12 are aligned. All xenoantibody sequences utilized for 
antibody modeling were derived from sequences elicited in baboons against 
GTKO/hCD55/hCD59/hHT neonatal islet-like cell cluster transplantation (13). (A) 
Computer modeling predicts that structure of the heavy chain complementarity 
determining region (CDR) 3 displays a greater degree of structural variation than the 
light chain CDR3. In contrast, the structures of the CDR loops 1 and 2 of both the (B) 
heavy and (C) light chain display minimal variation. CDR loops are highlighted in 
yellow for emphasis. Yellow – homologous region of complementarity determining 
region (CDR); black – non-homologous region of CDR; teal – Framework regions; 
HCDR – heavy CDR; LCDR – light chain CDR. 
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Neither gabexate mesilate nor clonidine were included in the list of molecules 
predicted to bind xenoantibody. However, four structurally related azole anti-fungal 
agents were predicted to bind all three xenoantibody structural models with high affinity 
including ketoconazole, voriconazole, clotrimazole, and oxiconazole. Given that both 
voriconazole and oxiconazole were identified to inhibit xenoantibody by screening in 
vitro, we were prompted to retest all azole antifungals included in the NIH clinical 
collection. Unfortunately, no additional xenoantibody inhibitors were identified. 
Interestingly, both oxiconazole and voriconazole are the most structurally similar pair of 
these four drugs. Furthermore, they share a limited region of structural similarity with 
clonidine (Fig. 3), suggesting all three molecules may share a similar mechanism of 
inhibition. Of note, both voriconazole and oxiconazole likely bind directly to anti-non-
Gal xenoantibody given that they were both predicted in silico and identified in vitro. 
However, oxiconazole is only suitable for topical use and thus would not be appropriate 
for application as a xenoantibody inhibitor in vivo. Thus, further experiments did not 
include oxiconazole. 
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Figure 3. Voriconazole (A), oxiconazole (B), and clonidine (C), which were identified 
to inhibit anti-non-Gal IgM xenoantibody share a limited region of structural similarity 
suggesting they may inhibit xenoantibody utilizing a common mechanism. Molecules 
are depicted in three dimensions so as to highlight structural similarities. Grey – Carbon, 
white – hydrogen, red – oxygen, blue – nitrogen, green – chlorine, teal – fluorine. 
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Natural IgM Antibodies are Minimally Affected by Clonidine and Moderately Affected 
by Gabexate Mesilate and Voriconazole 
In order to determine whether the identified compounds could inhibit other 
antibody responses we tested their ability to interfere with natural IgM antibodies. Serum 
collected at day 14 after injection of NIS.A and NIS.B with GTKO PAECs was used as a 
source of antibody. This was essential because the identified compounds were known to 
inhibit IgM xenoantibody present at this time point. Ideally these compounds would not 
interact with natural antibodies which would suggest a high level of selectivity for anti-
non-Gal xenoantibodies. Gabexate mesilate and voriconazole displayed a moderate level 
of selectivity while clonidine demonstrated a high level of selectivity for anti-non-Gal 
IgM xenoantibody (Fig. 4). Gabexate mesilate and voriconazole displayed minimal 
interference of binding to laminin (Fig 4A-B), however both inhibited a proportion of 
natural antibodies that bound to thyroglobulin (16-38%; Fig. 4C-D) and ssDNA (13-50%; 
Fig. 4E-F). In contrast, clonidine inhibited a relatively small proportion of anti-ssDNA 
antibody binding in only one animal (19 ± 1 % in NIS.B; Fig. 4E-F), and had no 
significant effect on other types of natural antibodies examined. Therefore, in this 
context, clonidine displayed the highest level of selectivity for anti-non-Gal IgM 
xenoantibody. 
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Figure 4. Clonidine has minimal impact on natural IgM antibodies from non-
immunosuppressed rhesus monkeys. Gabexate mesilate (GM), clonidine (Clon), and 
voriconazole (VCZ) were tested for their ability to inhibit natural antibodies against (A-
B) laminin, (C-D) thyroglobulin, and (E-F) single stranded DNA (ssDNA). These drugs 
minimally interfere with anti-laminin IgM natural antibodies (8 ± 2% inhibition by 
VCZ). However, both gabexate and voriconazole inhibit natural IgM antibodies against 
thyroglobulin (16-38%) and ssDNA (13-50%). In contrast, clonidine only inhibited anti-
ssDNA antibodies from one of the two non-immunosuppressed animals (19 ± 1%). 
Values are reported as mean optical density (OD) and % inhibition ± the standard error 
of the mean; * indicates P <0.05 compared to day 14 without drug; Non-
immunosuppressed animals – NIS.A and NIS.B; % inhibition = 100% x [D14OD – (D14 
with drug)OD]/(D14OD). 
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Clinically Relevant Small Molecule Drugs can Provide Added Benefit In Vitro in 
Combination with Anti-Idiotypic Antibody In Vivo 
While these drugs can inhibit xenoantibody when utilized in isolation, it is more 
likely that they will be used in combination with other immunosuppressive reagents in 
vivo. We sought to test whether they could provide additional benefit in the context of 
pre-treatment with an anti-non-Gal selective anti-idiotypic antibody. Three rhesus 
monkeys (AIA.A-C) were pre-treated with anti-idiotypic antibody intravenously on 
experimental days -28, -21, and -14 before intravenous injections with GTKO PAECs on 
experimental day 0 (Fig. 5A). Serum collected from these animals on experimental day 
14 was utilized as a source of induced xenoantibody for this experiment. Clonidine was 
able to reduce anti-non-Gal IgM detectable in serum samples from all animals tested (Fig. 
5B). For one animal (AIA.A), the combination of clonidine and gabexate mesilate 
inhibited anti-non-Gal IgM to a greater extent than either drug alone. Additionally, the 
combination of gabexate mesilate and voriconazole inhibited detection of anti-non-Gal 
IgM binding in serum samples from two of three animals (AIA.A and AIA.B). It should 
be noted that the levels of anti-non-Gal IgM detected after combination treatment [anti-
idiotypic antibody + small molecule(s)] were comparable to, or lower than that of the 
matched naïve animal (Fig. 5C) with only one exception (AIA.A + gabexate mesilate). 
 137 
 
  A 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
0.00
0.25
0.50
0.75
1.00
N
aï
ve
D
1
4
 +
 G
M
D
1
4
 +
 C
lo
n
D
1
4
 +
 V
C
Z
D
1
4
 +
 G
M
 +
 C
lo
n
D
1
4
 +
 G
M
 +
 V
C
Z
D
1
4
 +
 C
lo
n
 +
 V
C
Z
N
aï
ve
D
1
4
 +
 G
M
D
1
4
 +
 C
lo
n
D
1
4
 +
 V
C
Z
D
1
4
 +
 G
M
 +
 C
lo
n
D
1
4
 +
 G
M
 +
 V
C
Z
D
1
4
 +
 C
lo
n
 +
 V
C
Z
N
aï
ve
D
1
4
 +
 G
M
D
1
4
 +
 C
lo
n
D
1
4
 +
 V
C
Z
D
1
4
 +
 G
M
 +
 C
lo
n
D
1
4
 +
 G
M
 +
 V
C
Z
D
1
4
 +
 C
lo
n
 +
 V
C
Z
O
D
 4
9
0
 n
m
AIA.A
AIA.B
AIA.C
0.0
0.2
0.4
0.6
0.8
1.0
D
0
D
1
4
D
1
4
 +
 G
M
D
1
4
 +
 C
lo
n
D
1
4
 +
 V
C
Z
D
1
4
 +
 G
M
 +
 C
lo
n
D
1
4
 +
 G
M
 +
 V
C
Z
D
1
4
 +
 C
lo
n
 +
 V
C
Z
D
0
D
1
4
D
1
4
 +
 G
M
D
1
4
 +
 C
lo
n
D
1
4
 +
 V
C
Z
D
1
4
 +
 G
M
 +
 C
lo
n
D
1
4
 +
 G
M
 +
 V
C
Z
D
1
4
 +
 C
lo
n
 +
 V
C
Z
D
0
D
1
4
D
1
4
 +
 G
M
D
1
4
 +
 C
lo
n
D
1
4
 +
 V
C
Z
D
1
4
 +
 G
M
 +
 C
lo
n
D
1
4
 +
 G
M
 +
 V
C
Z
D
1
4
 +
 C
lo
n
 +
 V
C
Z
O
D
 4
9
0
 n
m
AIA.A
AIA.B
AIA.C
* 
* 
* 
* 
* * 
* 
ŧ 
D0 D14 
AIA 
D -28 
AIA 
D -21 
AIA 
D -14 
Immunization 
 138 
 
 
 
 
 
 
 
 
 
Figure 5. In all animals tested, clonidine (Clon) is able to inhibit anti-non-Gal IgM 
detectable by ELISA at day 14 after immunization of anti-idiotypic antibody pre-treated 
rhesus monkeys (AIA.A, AIA.B, and AIA.C). (A) The in vivo experimental time line. (B) 
In one animal (AIA.A), the combination of clonidine and gabexate (GM) was significantly 
more effective than either drug alone. In contrast, the only other effective treatment in this 
setting was the combination of gabexate and voriconazole (VCZ), which was able to inhibit 
xenoantibody in two of the three animals tested. (C) After pre-treatment with anti-idiotypic 
antibody and inhibition of residual xenoantibody only AIA.A + GM displays significant 
binding to non-Gal antigen above that of the naïve animal (dashed line/dark bar). Values 
are reported as mean optical density (OD) ± the standard error of the mean; * indicates P 
<0.05 compared to day 14 without drug. Ŧ indicates p < 0.05 that the detectable antibody 
is above naïve levels. 
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Anti-Idiotypic Antibody and Clonidine have Marginal Impact on Natural Antibodies 
Because it was effective in all animals tested, further experimentation in the 
context of pre-treatment with anti-idiotypic antibody utilized clonidine alone or in 
combination with gabexate mesilate. In order to investigate the impact of anti-idiotypic 
antibody and small molecule drugs on other antibody responses, we tested their ability to 
interfere with natural IgM antibodies (Fig. 6). Three animals were tested for the impact 
on natural antibodies against laminin, thyroglobulin, and ssDNA. Of the nine possible 
combinations [animals x (natural antibody)], only two demonstrated a significant change 
due to anti-idiotypic antibody. AIA.B demonstrated a 32 ± 2% reduction of anti-laminin 
antibody levels (Fig. 6A-B) but no change in anti-thyroglobulin antibodies (Fig. 6C-D) 
while AIA.A demonstrated a 32 ± 1% reduction of anti-ssDNA antibodies (Fig. 6E-F). 
Thus, pre-treatment with the anti-idiotypic antibody was associated with only marginal 
changes in natural antibody levels. In this context, clonidine displayed minimal inhibition 
of the natural antibodies present at experimental day 14 (Fig. 6). Clonidine by itself 
displayed only marginal inhibition (10-21%) of natural anti-laminin IgM antibodies in 2 
of 3 animals but did not impact any other classes of natural antibodies (Fig. 6A-B). This 
suggests clonidine is highly selective for anti-non-Gal IgM xenoantibody. In contrast, 
gabexate mesilate, alone or in combination with clonidine inhibited natural antibodies 
against laminin, thyroglobulin, and ssDNA. Gabexate mesilate inhibited anti-laminin 
antibodies from each animal (28-70%), anti-ssDNA antibodies from two animals (AIA.A 
and AIA.C; 45-56%), and anti-thyroglobulin antibodies from one animal (AIA.A; 42%). 
Thus, gabexate mesilate appears to have little specificity for anti-non-Gal IgM 
xenoantibody in this context. 
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Figure 6. Clonidine (Clon) has minimal impact on natural IgM antibodies after pre-
treatment with anti-idiotypic antibody and immunization with GTKO pig endothelial 
cells. (A-B) Clonidine did inhibit some natural antibodies against laminin (10-21%). 
However, clonidine did not interfere with natural IgM antibodies against (C-D) 
thyroglobulin or (E-F) single stranded DNA (ssDNA) in this context. In contrast, 
gabexate frequently inhibited natural antibodies against laminin (28-70%), ssDNA (34-
56%), and thyroglobulin (42 ± 11%). Values are reported as mean optical density (OD) 
± the standard error of the mean; * indicates P < 0.05 compared to day 14 without drug 
(dark bar) unless otherwise indicated; % inhibition = 100% x [D14OD – (D14 with 
drug)OD]/(D14OD). 
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Clonidine Inhibits Anti-Non-Gal IgM Xenoantibody Elicited in Rhesus Monkeys after 
Transplantation with Fetal Pig Islet-Like Cell Clusters 
Clonidine was further tested for the ability to inhibit IgM xenoantibody elicited in 
rhesus monkeys in response to transplantation with fetal pig islet-like cell clusters. Two 
adult rhesus monkeys were transplanted with porcine islet-like cell clusters isolated from 
wild type fetal pigs at day 66 of gestation (15). Although we have studied the anti-gal 
carbohydrate antibody response of these animals, they also demonstrated a notable anti-
non-Gal IgM xenoantibody response (Fig. 7). Serum collected at day 8 after 
xenotransplantation was used as a source of elicited anti-non-Gal xenoantibodies. As 
determined by ELISA, clonidine was able to inhibit over 50% of the anti-non-Gal IgM 
xenoantibodies elicited in both monkeys. 
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Figure 7. Clonidine (Clon) is able to inhibit anti-non-Gal IgM elicited in rhesus 
monkeys (ISELT.1-2) after transplantation with fetal islet-like cell clusters (15 x 106). 
Although we previously studied the anti-Gal carbohydrate xenoantibody response of 
these animals (15) they also demonstrated an anti-non-Gal IgM xenoantibody response. 
Serum used in this study was collected just before transplantation (Pre-Tx) and on post-
operative day 8 (Post-Tx). Clonidine was able to inhibit 64 ± 3% of anti-non-Gal IgM 
elicited in ISLET.1 and 53 ± 3% elicited in ISLET.2. Values are reported as mean optical 
density (OD) ± the standard error of the mean; * indicates P < 0.05; % inhibition = 100% 
x [D14OD – (D14 with drug)OD]/(D14OD – D0OD). 
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Clonidine Selectively Inhibits Anti-Non-Gal IgM Xenoantibody Elicited in Baboons 
after GTKO Pig Kidney Transplantation 
IgM xenoantibodies elicited by kidney xenotransplantation in the absence of 
additional immunosuppression were measured with or without the addition of clonidine 
in vitro. Circulating anti-non-Gal xenoantibody is known to be dramatically reduced by 
absorption onto the graft in the first few days after transplant (26). Thus, there were only 
detectable xenoantibody responses in two of the six baboons whose GTKO multiple 
transgenic kidney xenografts survived over 100 hours (KIDNEY.1 and KIDNEY.2; Fig. 
8A-B). Serum samples utilized in this study were collected just before transplant and at 
the time of rejection. As determined by ELISA, clonidine was able to inhibit 28 ± 2% and 
75 ± 1% of the elicited anti-non-Gal IgM xenoantibody response of these two animals 
(Fig. 8A-B).  
All six baboons were previously immunized and routinely boosted every 5 years 
for tetanus. This allowed us to determine the impact of clonidine on the levels of a 
clinically relevant set of protective antibodies elicited by vaccination. Anti-tetanus toxoid 
IgG antibodies were unaffected by clonidine in five of six animals (Fig. 8C). In the other 
animal (KIDNEY.1), clonidine significantly reduced the detectable anti-tetanus toxoid 
IgG in post-transplant serum by 0.084 IU/ml. However, the remaining antibody (0.19 
IU/ml) was still well above 0.10 IU/ml which is known to provide substantial protection 
against tetanus (27, 28). Furthermore, because clonidine was able to inhibit an equal or 
greater percentage of anti-non-Gal xenoantibodies from both animals that demonstrated a 
xenoantibody response, we considered this outcome to show a high degree of selectivity 
in this experimental setting. 
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Figure 8. Clonidine (Clon) is able to selectively inhibit the anti-non-Gal IgM response 
elicited in baboons in response to GTKO multitransgenic kidney xenotransplantation. 
Serum was collected before transplantation (pre-Tx) and at rejection (post-Tx) from six 
baboons (KIDNEY.1-6). (A-B) Xenografts from two animals (KIDNEY.1-2) were 
rejected late enough (> 100 hours) to detect an anti-non-Gal IgM xenoantibody 
response. Clonidine was able to inhibit 28 ± 2% of IgM xenoantibody elicited in 
KIDNEY.1 and 75 ± 1% elicited in KIDNEY.2. Values are reported as mean optical 
density (OD) or % inhibition ± the standard error of the mean; % inhibition = 100% x 
[D14OD – (D14 with drug)OD]/(D14OD – D0OD) (C) Clonidine only reduced 
detectable anti-tetanus toxoid IgG from one of six animals. However, clonidine inhibits 
anti-non-Gal IgM in all animals, which demonstrated a detectable xenoantibody 
response suggesting it is highly selective. Anti-tetanus toxoid IgG is known to be 
protective at 0.1 IU/ml (dashed line). Values are reported as IU/ml ± the standard error 
of the mean. * indicates P < 0.05. 
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Discussion 
In this study, we identified three clinically relevant small molecule drugs with the 
ability to selectively inhibit anti-non-Gal IgM xenoantibody. Clonidine maintained this 
capability when utilized against xenoantibodies elicited against pig endothelial cells as 
well as islet and kidney xenografts. Furthermore, clonidine was effective against elicited 
xenoantibody from all animals that demonstrated a xenoantibody response, including 
baboons and rhesus monkeys. Given that clonidine is consistently effective in such 
diverse experimental models of xenotransplantation it is a highly promising candidate for 
in vivo studies. 
The small molecule drugs identified in our current study may also have beneficial 
effects beyond selective inhibition of anti-non-Gal xenoantibody. For instance, clonidine 
has been used clinically in multiple settings for decades (25, 29-35) and has well 
documented effects on the immune system. It has recently been found to prevent 
neutrophil extravasation by stabilizing endothelial cell expression of adherens junctional 
molecules (36). Clonidine can also reduce serum concentrations of inflammatory 
cytokines such as IL-1β and IL-6 in healthy young adults (37) and mitigate the post-
operative rise of serum TNF-α in response to lower-extremity revascularization (38). 
Furthermore, voriconazole can be an effective antifungal prophylactic treatment (39) 
while gabexate mesilate’s anticoagulant effect has been demonstrated to improve islet 
engraftment in a syngeneic rat model of islet transplantation (40). Xenoislet engraftment 
could therefore be enhanced by inhibition of the instant blood mediated inflammatory 
reaction as well as by inhibition of anti-non-Gal xenoantibody.  
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In our previous work we identified an experimental small molecule, JMS022, 
from the NCI Diversity Set III that was capable of inhibiting xenoantibody elicited by 
GTKO PAECs (14). While this library was large enough and sufficiently structurally 
diverse to enhance the likelihood of successful in silico screening, it was composed of 
small molecules with unknown safety profiles. The NIH Clinical Collections were 
selected for the current study because they consist almost entirely of drugs that have been 
in phase I-III clinical trials. Additionally, all compounds are available commercially. 
These two qualities dramatically enhanced the likelihood that any small molecule 
inhibitors of anti-non-Gal xenoantibody could be advanced rapidly and tested in vivo for 
efficacy in large animals. Furthermore, screening all 727 drugs in vitro ensured that we 
would not miss compounds that may not come up in virtual screening. 
It is of particular interest that clonidine was able to effectively inhibit post-
transplant/immunization xenoantibody from all animals that demonstrated a 
xenoantibody response. Furthermore, clonidine was effective against anti-non-Gal IgM 
xenoantibody elicited by endothelial cells, islet-like cell clusters, and kidney 
xenotransplantation. This is consistent with our previous analysis suggesting that the 
majority of the anti-non-Gal IgM antibody response is structurally restricted in multiple 
settings (12, 13). However, the previously identified experimental compound JMS022 
was only capable of inhibiting the IgM xenoantibody response of 3 of 5 rhesus monkeys 
tested (NIS.A, AIA.A, and AIA.C) (14). This suggested some degree of structural 
variation at the site to which JMS022 binds. We speculate that this may be due to 
previously noted variation in the structures of the CDR3 loops of the antibody heavy and 
light chains (13).  
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Our refined in silico screening methodology incorporates the structural variation 
of the CDR3 loops. Using this modified algorithm, oxiconazole and voriconazole, but not 
clonidine or gabexate, were both predicted to bind anti-non-Gal IgM xenoantibody with 
high affinity. This suggests that voriconazole and oxiconazole were capable of inhibiting 
xenoantibody directly. However, clonidine shares a limited region of structural similarity 
suggesting all three molecules may inhibit xenoantibody via a common mechanism. A 
recent analysis of 227 antigen-antibody complexes suggests that tyrosine and tryptophan 
residues in the hypervariable region almost exclusively interact with the corresponding 
target antigen (41). Furthermore, these side chains are generally responsible for a large 
proportion of the binding free energy. Thus, hypervariable region tyrosine and tryptophan 
residues which are conserved in all three xenoantibody structural models (i.e. W32 in the 
light chain CDR1, Y32, and Y33 in the heavy chain CDR1, and Y50, Y58, and Y59 in 
the heavy chain CDR2; (13)) are highly likely to mediate both xenoantibody-xenoantigen 
interactions and interact with small molecule inhibitors. The region of limited structural 
similarity shared between clonidine, voriconazole, and oxiconazole is likely to interact 
with these side chains via pi-pi interactions and halogen bonding. Unfortunately, neither 
of these mechanisms are accurately represented by the most accessible virtual screening 
or molecular docking programs since these programs utilize atomic point-charge based 
calculations (42-45). Therefore, further refinement is necessary to enable us to use 
computational modeling to more accurately predict which molecules will selectively 
inhibit xenoantibody. 
In the current work we utilized inhibition of natural antibodies against laminin, 
thyroglobulin, and ssDNA as a proxy for the ability of small molecule drugs to interfere 
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with non-xenoantibody responses. The source of natural antibodies in primates is 
controversial (46, 47). However, natural antibodies are thought to contribute not only to 
immune pathologies (48) but also to normal physiologic processes (49) including 
immune surveillance (50). Gabexate mesilate and voriconazole reduced natural antibody 
binding in the majority of animals tested, whereas clonidine did not. This suggests 
clonidine is a highly selective inhibitor of anti-non-Gal IgM xenoantibody. 
Interference with the anti-tetanus antibody response elicited by vaccination 
represents a more clinically relevant measure of the ability of small molecules to affect 
non-xenoantibody responses. Clonidine only inhibited this protective induced category of 
antibodies in one of six animals tested. Furthermore, the detectable anti-tetanus toxoid 
IgG in this animal remained significantly above the lower limits of what is known to be 
protective in spite of inhibition by clonidine. Importantly, clonidine still displayed greater 
inhibition of anti-non-Gal IgM xenoantibody. Thus, clonidine displayed clinically 
relevant selectivity for anti-non-Gal xenoantibody while demonstrating efficacy in all 
animals that elicited a xenoantibody response. 
It should be emphasized that no treatment in isolation, neither anti-idiotypic 
antibody nor small molecule, was capable of fully inhibiting the anti-non-Gal IgM 
xenoantibody response in all animals. It was only when both reagents were utilized in 
combination that the xenoantibody detected at experimental day 14 was comparable to or 
below those levels found in the naïve animals. Thus, these small molecule inhibitors of 
anti-non-Gal antibody are likely to be the most effective when utilized in combination or 
in the context of additional reagents.  
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We have demonstrated that clonidine is effective in a diversity of settings and can 
inhibit anti-non-Gal xenoantibodies elicited not only by kidney or fetal islet-like cell 
cluster xenotransplantation, but also by pig endothelial cells. Together, these results 
indicate that it is feasible to block the initial anti-non-Gal IgM response in a targeted 
fashion, and also that the elicited xenoantibody responses are structurally related. Further 
scientific inquiry in these models should be focused in vivo. However, selective inhibitors 
are likely to be beneficial in these and related settings. For instance, selective inhibitors 
may be able to supplement or replace B cell-depletion which is currently required to 
extend GTKO cardiac xenotransplantation (6, 8). Thus, reagents capable of inhibiting 
anti-non-Gal xenoantibodies in a targeted fashion are a fruitful area of inquiry, and are 
likely to enhance survival and/or function in multiple xenotransplantation settings. 
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CHAPTER FIVE 
CONCLUSIONS 
 
Discussion 
 
The purpose of this dissertation has been to 1) provide further molecular 
characterization of the elicited antibodies which mediate damage and rejection of porcine 
xenografts, and 2) to identify clinically applicable small molecules capable of selectively 
inhibiting these antibodies. Before this body of work there was only preliminary 
evidence, provided by our lab (1), that the majority of the anti-non-Gal antibody response 
was structurally related. However, the works described in chapters 2-4 now provide 
strong support for this theory. Perhaps most importantly, this perspective led us to 
identify a clinically relevant small molecule drug capable of inhibiting antibody elicited 
in multiple xenotransplantation settings. However, along the way, and quite 
unexpectedly, our initial molecular analysis of anti-non-Gal antibody response led us to 
challenge longstanding theories with regard to the nature of xenoantibodies. 
Even before the generation of GTKO pigs, the dogma has been that antibodies 
binding to the cell surface initiate xenograft damage. As such, previously utilized 
methods of identifying novel xenoantigens have focused on either membrane bound 
carbohydrates (2-4) or membrane bound proteins (5-7). It is therefore notable that FVIII 
is the first, and currently the only, xenoantigen identified to date that is secreted rather 
than membrane bound. However, FVIII is unlikely to be the only soluble porcine antigen 
with functional consequences. In addition to further defining the role of FVIII in 
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xenograft damage, studies seeking to identify novel soluble pig antigens are likely to 
provide valuable insight into hidden aspects of xenograft rejection.  
In chapter three, we found that all four rhesus monkeys tested had pre-existing 
antibodies capable of inhibiting recombinant human clotting factor VIII (FVIII). This is 
likely due to amino acid differences between human and rhesus FVIII. In a similar 
fashion, 17% of apparently healthy individuals with FVIII polymorphisms have FVIII 
inhibitors which inhibit donor FVIII, but not autologous FVIII (8). 
The apparent rise in FVIII inhibitor titer after xenotransplantation is also likely 
due to the low level of amino acid homology shared between pig and primate FVIII. As 
previously discussed in chapter three, this is likely to contribute to pathology in multiple 
pre-clinical models of xenotransplantation. More importantly, it is also likely to impact 
pig-to-human xenotransplantation. Patients with hemophilia A treated with porcine FVIII 
have been shown to have elevated anti-human and anti-porcine FVIII titers in spite of 
immunosuppression (9-11). Furthermore, the elicited inhibitors can act on FVIII from 
one or both species. 
At this time the functional impact on coagulation parameters in the context of 
xenotransplantation is still speculative. Even though experiments in non-human primates 
are the gold standard in this field, they are unlikely to fully reflect the clinical 
implications of elicited clotting factor inhibitors. GTKO pigs, humans, and non-human 
primates are recognized as having different coagulation parameters (12, 13). Non-human 
primates are hyper-coagulable, compared to humans, while GTKO pigs are relatively 
similar. However, GTKO pigs have higher levels of clotting factors V, VIII, IX, and XI 
and lower levels of II, VII, and X (14).  
 160 
Even in successful xenotransplantation the resulting hemostatic profile is likely to 
depend on what type of organ is being transplanted with differences dependent on the 
varying characteristics of each organ’s vasculature. The liver is considered to be the 
major source of clotting factors, including FVIII. However, in humans clotting FVIII is 
also known to be synthesized and released by endothelial cells in the vascular beds of the 
dermis, aorta, intestine, kidney, and lung (15-17). Thus, FVIII inhibitors are likely to 
develop if any these tissues and organs undergo xenotransplantation.  
In chapter three, we demonstrated that antibodies which inhibit human FVIII were 
elicited after aortic endothelial cell or pancreatic islet xenotransplantation. While 
expression of FVIII in pig aortic endothelial cells is well known (18), expression of FVIII 
in pancreatic islet endothelial cells has not been investigated. Endothelial cells do make 
up the majority of non-endocrine cells within an intact islet however, after isolation and 
culture of mouse islets for only 4 days endothelial cells amount to only 5% of their initial 
quantity (19). Those utilized in our study were only cultured for six days (20), making it 
plausible that FVIII expression in these isolated islets could have elicited an antibody 
response. However, the expression of FVIII should be investigated in freshly isolated and 
cultured porcine islets. If culturing isolated islets for longer than six days can reduce 
immunogenicity, it would make for an easy way to reduce antibody-mediated islet 
damage. However, mitigating damage to fully vascular organs will be more challenging. 
Importantly, in chapter 4, we were able to identify a small molecule drug capable 
of inhibiting a significant portion of post-transplant anti-non-Gal antibody in multiple 
xenotransplantation models. This suggests that each of these settings share common 
immunogens. It is particularly interesting that this drug (clonidine) was able to inhibit 
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post-transplant anti-non-Gal antibody from all animals tested. This reinforced our 
previous analysis in chapter two which suggested that the humoral response to 
xenotransplantation is primarily composed of structurally related antibodies. However, 
one reagent utilized in isolation has never been able to inhibit more than 75% of elicited 
antibody. This could be due to structural variation of the elicited antibodies, or just as 
likely insufficient affinity of clonidine for elicited anti-non-Gal antibody. 
Additionally, the question remains as to whether clonidine is capable of inhibiting 
anti-non-Gal antibodies elicited in humans. Non-human primates and humans have been 
noted to have minor sequence variations in their antibodies directed at the Gal antigen 
(21, 22). In the case of anti-Gal antibodies, amino acids important for contact with the 
antigen were conserved between species, however this may not be sufficient for anti-non-
Gal antibodies to maintain an inhibitory interaction with clonidine. 
In humans, typhoid vaccination has been associated with lower pre-existing anti-
non-Gal IgG titers while influenza vaccination has been associated with higher pre-
existing anti-non-Gal IgG titers (23). This association between anti-non-Gal antibody 
titer and vaccination suggests that selective inhibition of antibodies directed against 
GTKO pig xenografts could also impact protective immune responses. In chapter 4 we 
chose to measure the impact on anti-tetanus titer because these baboons had received 
regular tetanus boosters. In vitro analysis demonstrated clonidine inhibited anti-tetanus 
antibodies from one animal. In this case, the anti-tetanus titer of this animal was still 
considered protective after the addition of clonidine, though this may not be the case in 
all settings.  
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The immunoglobulin light chain gene identified in chapter 2 can encode 
antibodies against tetanus toxoid (24). This likely explains why clonidine was able to 
inhibit a portion of anti-tetanus antibodies from one animal in chapter 4. Additionally, the 
immunoglobulin heavy chain genes identified to encode anti-non-Gal antibodies, IGHV3-
66 and IGHV3-21, can both encode antibodies against influenza (25-27). Therefore, it is 
feasible that clonidine, and/or other selective inhibitors, may impact susceptibility to the 
flu. However, it is notable that, unlike the anti-non-Gal response, the antibody responses 
against tetanus and influenza are encoded by a diversity of antibody germline gene 
progenitors. Therefore, as we saw in chapter 4, after treatment with selectively inhibitory 
reagents, most individuals should still demonstrate protective antibody titers. Even so, 
early experimentation with clonidine, and other selective reagents, in xenotransplantation 
should include monitoring of protective antibody titers. It is notable though, that 
clonidine has been utilized in clinical medicine since 1966 (28) and as of yet has not been 
linked to any immune vulnerability. 
 
Future Directions 
While the efficacy of clonidine needs to be assessed in vivo using large animals in 
the context of the most commonly utilized immunosuppressive regimens, it also will be 
important to test in a variety of other settings. Our lab has provided preliminary evidence 
suggesting that a combination of reagents which selectively inhibit anti-non-Gal 
antibodies would be more beneficial than either reagent alone [see chapter 4 and (29)]. At 
least two selective inhibitors were required to reduce the post-transplant anti-non-Gal 
antibody to levels below or comparable to those present before transplantation. As of yet, 
this remains to be tested when both reagents are administered in vivo.  
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Not all clinically relevant drugs are included in the NIH clinical collection. 
Therefore, we could still feasibly identify more inhibitory reagents that would be 
immediately useful in large animal studies. Initial screening for additional inhibitory 
small molecules should focus on clinically relevant drugs with chemical structures 
similar to clonidine. However, there are only a limited number of drugs with immediate 
clinical relevance. Therefore, it will also be important to screen small molecule libraries 
containing experimental compounds with chemical features which are related to, and 
build off of, a clonidine (or imidizoline aryl halide) molecular scaffold. This would allow 
refinement of clonidine affinity and selectivity. Additionally, screening of experimental 
compounds should include small molecules structurally unrelated to clonidine. However, 
due to the sheer number of small molecules available for testing this would be more 
feasible after more detailed analysis of the xenograft-rejection antibody response and 
refinement of computational modeling. 
More accurate computational modeling of molecular interactions would enhance 
our in silico prediction, including analysis of antigen-antibody and small molecule-
antibody interactions. As previously mentioned in chapter 4, until recently the most 
accessible virtual screening and/or molecular docking programs utilized atomic point-
charge based calculations (30-33). Thus, these programs could not accurately represent 
all intermolecular interactions (halogen bonding; pi-pi stacking) likely to be important for 
interaction with clonidine. Notably, the latest version of Schrödinger’s Glide molecular 
docking software can now take these into account and will be important for future 
molecular analysis and prediction. 
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Much of what we have already proposed can, with some finesse, be applied to 
pre-existing anti-non-Gal antibodies. Most people have levels too low to precipitate 
delayed humoral xenograft rejection without an adaptive response, which can be negated. 
However, it is still likely that pre-existing antibodies will affect long term damage of 
cardiac xenografts (34). Furthermore, recent experiments have provided evidence which 
suggests that when the adaptive response is suppressed, pre-existing antibodies still 
contribute to graft dysfunction in kidney xenotransplantation (35). However, the 
molecular diversity of these pre-existing antibodies is virtually unknown. Therefore, 
molecular characterization and selective inhibition of pre-existing anti-non-Gal 
xenoantibodies is likely to be a fruitful area of inquiry. As was the case with anti-Gal 
antibodies, non-Gal xenoantigens characterized to date can be utilized to capture and 
purify pre-existing anti-non-Gal antibodies. Additionally, recent advances in mass 
spectroscopy make it possible to identify the amino acid sequences of heterogeneous 
antibodies isolated from serum (36). If these antibodies display limited structural 
diversity it may be possible to selectively inhibit them as well. 
Additionally, our lab has previously demonstrated that it is possible to induce 
tolerance to a specific antigenic structure in non-human primates (37). Following ablation 
of bone marrow using sublethal irradiation, rhesus monkeys were transplanted with 
autologous bone marrow transduced to express galactosyltransferase (GGTA1) using a 
lentiviral vector. This mitigated the antibody response against Gal, and expression was 
maintained in B cells and macrophages for as long as 355 days. In a similar vein, 
transducing autologous bone marrow to express the porcine FVIII C1 domain, or other 
xenoantigens, should induce tolerance and preempt rejection mechanisms initiated by 
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elicited antibody. Notably, there is already a large body of evidence, directed at patients 
with hemophilia A, to suggest this approach is feasible (38-40). Currently, the level of 
FVIII produced by the bone marrow in these settings can only cure mice with hemophilia 
A in some models. However, more universally, they have demonstrated induction of low 
level chimerism and tolerance. It is therefore feasible, that our lab could utilize these 
methods, along with our previous work in non-human primates, to induce long-term 
tolerance to pig FVIII. 
In conclusion, the results of this dissertation challenge long-standing 
presumptions with regard to the nature of xenoantigens and their role in antibody-
mediated xenograft rejection. Furthermore, these studies provide valuable insight into the 
nature of elicited antibodies, their interactions with FVIII, and their potential to be 
selectively inhibited by small molecule drugs. 
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